KR101774769B1 - Composition for medicinal herbal tea and manufacturing method of composition for medicinal herbal by supercritical fluid extraction and manufacturing method of carbonated beverage and health beverage thereof - Google Patents
Composition for medicinal herbal tea and manufacturing method of composition for medicinal herbal by supercritical fluid extraction and manufacturing method of carbonated beverage and health beverage thereof Download PDFInfo
- Publication number
- KR101774769B1 KR101774769B1 KR1020140178078A KR20140178078A KR101774769B1 KR 101774769 B1 KR101774769 B1 KR 101774769B1 KR 1020140178078 A KR1020140178078 A KR 1020140178078A KR 20140178078 A KR20140178078 A KR 20140178078A KR 101774769 B1 KR101774769 B1 KR 101774769B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- extract
- herbal
- composition
- insulin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 235000015092 herbal tea Nutrition 0.000 title claims abstract description 17
- 230000036541 health Effects 0.000 title claims abstract description 15
- 235000014171 carbonated beverage Nutrition 0.000 title claims abstract description 11
- 238000000194 supercritical-fluid extraction Methods 0.000 title claims abstract description 11
- 235000013361 beverage Nutrition 0.000 title abstract description 5
- 238000004519 manufacturing process Methods 0.000 title description 21
- 239000000284 extract Substances 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 54
- 241000411851 herbal medicine Species 0.000 claims abstract description 24
- 239000012159 carrier gas Substances 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 10
- 229940010454 licorice Drugs 0.000 claims abstract description 10
- 241000255789 Bombyx mori Species 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 235000000346 sugar Nutrition 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 19
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 18
- 239000007789 gas Substances 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 12
- 239000006188 syrup Substances 0.000 claims description 12
- 235000020357 syrup Nutrition 0.000 claims description 12
- 235000008504 concentrate Nutrition 0.000 claims description 10
- 235000011089 carbon dioxide Nutrition 0.000 claims description 9
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 235000011511 Diospyros Nutrition 0.000 claims description 6
- 244000236655 Diospyros kaki Species 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229930091371 Fructose Natural products 0.000 claims description 5
- 239000005715 Fructose Substances 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 239000000498 cooling water Substances 0.000 claims description 5
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 235000013736 caramel Nutrition 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 241001247821 Ziziphus Species 0.000 abstract description 60
- 238000000605 extraction Methods 0.000 abstract description 21
- 239000000463 material Substances 0.000 abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 4
- 235000011477 liquorice Nutrition 0.000 abstract description 2
- 241000202807 Glycyrrhiza Species 0.000 abstract 3
- 230000002363 herbicidal effect Effects 0.000 abstract 2
- 235000015097 nutrients Nutrition 0.000 abstract 2
- 244000061456 Solanum tuberosum Species 0.000 abstract 1
- 235000002595 Solanum tuberosum Nutrition 0.000 abstract 1
- 239000004009 herbicide Substances 0.000 abstract 1
- 235000012015 potatoes Nutrition 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 60
- 230000000694 effects Effects 0.000 description 33
- 102000004877 Insulin Human genes 0.000 description 30
- 108090001061 Insulin Proteins 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- 229940125396 insulin Drugs 0.000 description 29
- 206010012601 diabetes mellitus Diseases 0.000 description 23
- 239000003814 drug Substances 0.000 description 23
- 239000008103 glucose Substances 0.000 description 23
- 230000004190 glucose uptake Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 19
- 239000002032 methanolic fraction Substances 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 238000002835 absorbance Methods 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 210000001789 adipocyte Anatomy 0.000 description 12
- 238000009835 boiling Methods 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 108091006300 SLC2A4 Proteins 0.000 description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 8
- 230000003914 insulin secretion Effects 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 6
- 108060008724 Tyrosinase Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 231100000572 poisoning Toxicity 0.000 description 5
- 230000000607 poisoning effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 240000003768 Solanum lycopersicum Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 229940100389 Sulfonylurea Drugs 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000009702 cancer cell proliferation Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000015067 sauces Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 3
- 235000007516 Chrysanthemum Nutrition 0.000 description 3
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 229960002632 acarbose Drugs 0.000 description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000019606 astringent taste Nutrition 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 238000001354 calcination Methods 0.000 description 3
- 235000009120 camo Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000005607 chanvre indien Nutrition 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011487 hemp Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000008960 ketchup Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000003538 oral antidiabetic agent Substances 0.000 description 3
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000003507 refrigerant Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960001761 chlorpropamide Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 2
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 235000013882 gravy Nutrition 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MYGCFWRBKKQKCG-GBWOLBBFSA-N (z,2r,3s,4r)-hex-5-ene-1,2,3,4,6-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)\C=C/O MYGCFWRBKKQKCG-GBWOLBBFSA-N 0.000 description 1
- RXUWFHRBKJDCMV-UHFFFAOYSA-N 1-methylsulfanyltetrazole Chemical compound CSN1C=NN=N1 RXUWFHRBKJDCMV-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 1
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 229930185889 Epigomisin Natural products 0.000 description 1
- GWDFJIBHVSYXQL-SYTFOFBDSA-N Epigomisin O Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3[C@H](O)[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 GWDFJIBHVSYXQL-SYTFOFBDSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 238000006424 Flood reaction Methods 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 206010052534 Large intestinal haemorrhage Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001400472 Omiza Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- PLKFSXFJGNZAER-UHFFFAOYSA-N Tigloylgomisin O Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C(OC(=O)C(C)=CC)C(C)C(C)CC2=CC2=C1OCO2 PLKFSXFJGNZAER-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- FLUADVWHMHPUCG-OVEXVZGPSA-N Verbascose Natural products O(C[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](OC[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]3(CO)[C@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 FLUADVWHMHPUCG-OVEXVZGPSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- PLKFSXFJGNZAER-XXDSNBTQSA-N [(8R,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] (Z)-2-methylbut-2-enoate Chemical compound COc1cc2[C@H](OC(=O)C(\C)=C/C)[C@@H](C)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC PLKFSXFJGNZAER-XXDSNBTQSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940067621 aminobutyrate Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000021257 carbohydrate digestion Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000007593 dry painting process Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000000910 hyperinsulinemic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- -1 pregomoisin Natural products 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000019638 tenderness Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 239000005341 toughened glass Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- FLUADVWHMHPUCG-SWPIJASHSA-N verbascose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)O3)O)O2)O)O1 FLUADVWHMHPUCG-SWPIJASHSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels, liquid extracts in solid capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/22—Drying or concentrating tea extract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/54—Mixing with gases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/44—Supercritical state
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 한방차용 조성물 및 CO₂ 추출법에 의한 한방차 추출조성물 제조방법과 이를 이용한 탄산음료 및 건강음료 제조방법에 관한 것으로서, 보다 구체적으로는 천화분, 갈근, 생지황, 오미자, 감초, 의이인, 대추, 돼지감자로 이루어진 한방생약재 원료를 N₂ 또는 CO₂ 캐리어 기체를 이용하여 추출 및 농축하여 수득된 한방생약재 추출물 및 음료소재를 포함하도록 하기 위하여, 천화분 10∼20중량%, 갈근 5∼10중량%, 생지황 5∼10중량%, 오미자 5∼10중량%, 감초 5∼10중량%, 의이인 20∼50중량%, 대추 5∼10중량%를 포함하여 이루어짐을 특징으로 한다.
또한, 천화분 10∼20중량%, 갈근 5∼10중량%, 생지황 5∼10중량%, 오미자 5∼10중량%, 감초 5∼10중량%, 의이인 20∼50중량%, 대추 5∼10중량%의 중량비로 배합된 한방생약재 분쇄물을 CO₂또는 N₂캐리어 기체를 이용한 초임계 추출법으로 추출 및 농축하여 제조됨을 특징으로 한다.The present invention relates to a composition for a herbal composition and a method for preparing a herbal tea extract composition by a CO 2 extraction method, and a method for preparing a carbonated beverage and a health drink using the same. More particularly, In order to contain the herbal medicinal herb extract and the beverage material obtained by extracting and concentrating the herbal medicine raw material made of potatoes with the use of the N2 or CO2 carrier gas, it is preferable to add 10-20 wt% of silkworm, 5-10 wt% of Puerariae, 5 to 10% by weight of liquorice, 5 to 10% by weight of licorice, 20 to 50% by weight of nutrients, and 5 to 10% by weight of jujubes.
5 to 10 wt% of licorice, 5 to 10 wt% of licorice, 20 to 50 wt% of nutrient, 5 to 10 wt% of jujubate, 10 to 20 wt% of silkworm, 5 to 10 wt% By mass of the herbicidal herbicide pulverized by the method of the present invention is extracted and concentrated by a supercritical extraction method using CO 2 or N 2 carrier gas.
Description
본 발명은 한방차용 조성물 및 초임계 추출법에 의한 한방차 추출조성물 제조방법과 이를 이용한 탄산음료 및 건강음료 제조방법에 관한 것으로서, 보다 구체적으로는 천화분, 갈근, 생지황, 오미자, 감초, 의이인, 대추로 혼합하여 된 한방생약재 원료를 CO₂또는 N₂캐리어 기체를 이용하여 추출 및 농축하여 수득된 한방생약재 추출물 및 음료소재를 포함하는 한방차용 조성물 및 초임계 추출법에 의한 한방차 추출조성물 제조방법과 이를 이용한 탄산음료 및 건강음료 제조방법에 관한 것이다.The present invention relates to a method for preparing a herbal tea extract composition using a herbal composition and a supercritical extraction method, and a method for preparing a carbonated beverage and a health drink using the same. More particularly, the present invention relates to a method for preparing a herbal tea, A herbal medicine composition comprising a herbal medicine extract and a beverage material obtained by extracting and concentrating a mixed herbal medicinal raw material with a CO2 or N2 carrier gas and a method of preparing a herbal tea extract composition by a supercritical extraction method, And a method for manufacturing health beverages.
당뇨병은 비전염성 만성질환으로, 췌장의 β세포에서 분비되는 인슐린이 부족하거나 그 기능을 제대로 발휘하지 못하여 체내에서 포도당이 에너지원으로 이용되지 못하고 혈액내에 고농도로 남아 있다가 소변으로 배설되는 질환이다.Diabetes mellitus is a chronic non-communicable disease. Insulin secretion from pancreatic β-cells is insufficient or its function is not exerted. Therefore, glucose is not used as an energy source and remains in high concentration in the blood and excreted in the urine.
당뇨병은 그 발병원인 및 증상의 치료방법에 따라 크게 인슐린 의존형 당뇨병(Insulin dependent diabetes mellitus, IDDM, 제1형당뇨병)과 인슐린 비의존형 당뇨병(Non-insulin dependent diabetes mellitus, NIDDM, 제2형당뇨병)으로 분류된다.Diabetes mellitus is divided into two major categories: insulin dependent diabetes mellitus (IDDM), non-insulin dependent diabetes mellitus (NIDDM) and type 2 diabetes mellitus .
제1형당뇨병은 유전적 원인, 바이러스 감염 등에 의해 췌장 β세포의 기능이 저하되어 인슐린이 거의 분비되지 않은 상태로서, 주로 10~20대에 갑자기 발병하며, 소아형 당뇨병이라고도 한다.Type 1 diabetes is a condition in which the function of the pancreatic β cells is impaired due to genetic causes, viral infections, and insulin is rarely secreted. It occurs mainly in the 10th to 20th generations, and is also referred to as pediatric diabetes.
제2형당뇨병은 가족력, 비만, 스트레스, 식사의 잘못 또는 인슐린과 길항(拮抗)하는 약물 등에 의해 발병되는 것으로, 40대 이후에 잘 나타나며, 성인형 당뇨병이라고도 한다. 췌장에서의 인슐린 분비는 충분하지만 인슐린 저항성과 포도당 이용율이 정상인과 달라서 고인슐린혈증임에도 불구하고 혈당이 정상화 되지 않는다.Type 2 diabetes is caused by family history, obesity, stress, eating disorders, or drugs that antagonize insulin, and is well known in the forties and later, and is also called adult diabetes. Insulin secretion in the pancreas is sufficient, but insulin resistance and glucose utilization are different from normal people, so even though it is hyperinsulinemic, blood sugar is not normalized.
우리나라의 경우 당뇨병 환자의 90~95% 이상이 제 2형 당뇨병 환자이다.In Korea, more than 90% of diabetic patients are type 2 diabetic.
당뇨병의 증상은 다양하지만 대표적인 것으로 다뇨(多尿), 다음(多飮), 다식(多食)을 들 수 있는데, 높은 혈당치 때문에 포도당 및 과량의 수분이 삼투압에 의해 소변으로 배설되어 다뇨현상이 나타나고, 따라서 탈수증상으로 심한 갈증을 느껴 다음하게 되며, 또한 공복감을 느껴 음식을 많이 먹게 된다. 당뇨병 환자의 경우에는 포도당이 에너지원으로 이용되지 못하므로 이미 저장된 단백질과 지방을 에너지원으로 소모하게 되고, 이러한 현상들의 악순환으로 인해 체중감소를 초래하게 된다. 그러나 이러한 현상들은 당뇨병 발병 초기에 나타나는 급성증상에 불과하다.The symptoms of diabetes are various but typical examples are polyuria, multivitamins, multifetals. Due to high blood sugar levels, glucose and excessive water are excreted into the urine by osmotic pressure, resulting in polyuria Therefore, the symptoms of dehydration in the next thrilling feelings, and also feel hunger, eat a lot of food. In the case of diabetic patients, since glucose is not used as an energy source, it consumes already stored proteins and fats as an energy source, which causes weight loss due to the vicious circle of these phenomena. However, these symptoms are only acute symptoms that appear early in the onset of diabetes.
당뇨병을 동양의학적으로 분류하면 삼소(三消)라고 하여, 상소(上消), 중소(中消), 하소(下消)로 나뉘며, 그 원인은 폐열(肺熱), 위열(胃熱), 신열(腎熱)로 크게 분류된다.Diabetes mellitus is classified as Oriental medicine, and it is divided into three categories: upper, lower, and lower. The causes are lung, fever, And renal (renal) fever.
상소는 단순히 소갈(小渴)이라고도 하며, 심허(心虛)하여 사화(邪火)가 폐로 옮겨져 흉중이 번조(煩燥)하고 혀가 붉고 입술이 마르고 번갈(煩渴)하여 결과적으로 다음(多飮)하게 된다. 중소는 다뇨 및 다식을 주증상으로 하는데, 다뇨와 다식의 악순환으로 체중감소와 변비를 초래한다. 하소는 신소(腎消)라고도 하며, 구갈은 상소보다 덜하고, 소변량은 많으며 맥이 약하다.The appeal is also simply called 갈 갈 ((渴 渴), and the fire is moved to the lungs, the fire is frowned, the tongue is red, and the lips are dry and uncomfortable. As a result, ). Small and medium size is the main symptom of diarrhea and diarrhea. The vicious cycle of diarrhea and diarrhea causes weight loss and constipation. Calcination is also called renal excretion, and cigarette is less than appeal, urine is high, and the veins are weak.
갈증이 심한 상소는 잘 낫는 편이나 중소, 하소로 가면 치료가 어렵다. 갈증이 덜해지고 체중 감소가 급격히 나타나면 하소로 진행된 상태이다.Thirsty appellation is better, but it is difficult to treat it if you go to small, calcareous. When thirst is less and weight loss is rapid, calcination has progressed.
당뇨병은 조기에 발견하면 완치가 가능하며, 조기 치료함으로써 합병증을 미리 예방할 수 있다. 당뇨병 조기 발견은 당불내성 상태를 찾아내는 것이다. 당불내성이란 정상인과 당뇨환자의 중간단계로, 당뇨가 본격적으로 시작되기 전의 상태이다. 즉 혈당을 조절하고 인슐린을 분비하는 췌장 베타세포의 기능이 저하되거나 인슐린 저항성이 있어 포도당을 세포로 운반하는 능력이 저하되는 것을 말한다.Diabetes can be cured if detected early, and early treatment can prevent complications. Early detection of diabetes is to find a state of glucose intolerance. Diabetes mellitus is an intermediate stage between normal and diabetic patients, and is the state before the onset of diabetes. That is, it means that the function of pancreatic beta cells, which regulate blood sugar and secrete insulin, is decreased or insulin resistance is deteriorated and the ability to transport glucose to cells is decreased.
만약, 당뇨병의 치료가 늦어져서 만성이 되면 합병증으로 만성 혈관성질환을 유발하게 되는데, 당뇨병성 망막증(시력장애, 실명, 망막출혈), 당뇨병성 신증, 당뇨병성 말초 신경증으로 인해 인체의 전반적인 대사기능 및 감각기능이 저하된다.If chronic diabetes mellitus is delayed, chronic complications can lead to chronic vascular disease. Diabetic retinopathy (visual disturbance, blindness, retinal hemorrhage), diabetic nephropathy, diabetic peripheral neuropathy, Sensory function is deteriorated.
현재 사용되고 있는 당뇨병 치료제는 경구용 혈당강하제와 인슐린 주사제로 크게 구분된다. 일반적으로, 체내에서 인슐린 분비가 없는 인슐린 의존형 당뇨병 환자나 임신성 당뇨병 환자, 경구용 혈당강하제로 혈당조절이 제대로 안되는 인슐린 비의존형 당뇨병 환자에게는 인슐린 주사를 투여하고, 식사용법과 운동요법을 병행함에도 불구하고 적절한 혈당조절이 되지 않는 인슐린 비의존형 당뇨병 환자는 경구용 혈당강하제를 복용하게 하는 것이 통설이다.The currently used diabetes medicines are broadly divided into oral hypoglycemic agents and insulin injections. In general, insulin-dependent diabetes mellitus or gestational diabetes mellitus patients who do not have insulin secretion in the body, insulin-dependent diabetes mellitus patients whose insulin-dependent diabetes mellitus does not have adequate blood glucose control due to oral hypoglycemic agents, insulin injections, It is widely accepted that patients with non-insulin dependent diabetes mellitus who do not have adequate blood glucose control are given oral hypoglycemic drugs.
일반적으로 이용되는 경구용 혈당강하제는 설포닐우레아계(sulfonylureas) 약물과 비구아니드계(biguanides) 약물 및 티아졸리딘디온계(thiazolidinedione) 약물 등이 있다.Commonly used oral hypoglycemic agents include sulfonylureas drugs, biguanides drugs, and thiazolidinedione drugs.
설포닐우레아계 약물로는 글리피자이드, 글리클라자이드, 글리퀴돈, 글리벤클라마이드, 클로르프로파마이드 등이 있으며, 췌장에서 인슐린 분비를 촉진하는 작용을 나타낸다. 그러므로, 이들은 췌장에서 인슐린 분비가 전혀 없는 인슐린 의존형 당뇨병 환자, 췌장에서 인슐린 분비능력이 상대적으로 감소된 인슐린 비의존형 당뇨병 환자, 가임기 여성에게는 사용할 수 없는 문제점이 있다. Sulfonylurea drugs include glipizide, glyclazide, glycidone, glibenclamide, and chlorpropamide, which act to promote insulin secretion in the pancreas. Therefore, they have problems that can not be used for insulin-dependent diabetes mellitus patients who have no insulin secretion in the pancreas, insulin-dependent diabetes mellitus patients whose insulin secretory ability is relatively decreased in the pancreas,
또한, 이들 약물은 과용량을 투여하거나, 공복시에 투여하는 경우에는 저혈당을 초래하며 피부발진, 황달, 식욕부진, 오심(구역), 설사 등의 부작용도 나타난다. 특히 클로르프로파마이드 등의 반감기가 긴 약물(12~36시간)은 체내에 축적되어 저혈당을 일으킬 위험이 매우 높다. 또한, 대부분의 설포닐우레아계 약물은 간에서 대사되어 신장으로 배설되므로 간기능 및 신기능장해 환자에게는 주의하여 사용하여야 한다.In addition, these drugs cause hypoglycemia when administered in an overdosage dose or fasting, and side effects such as skin rash, jaundice, anorexia, nausea (diarrhea) and diarrhea also appear. In particular, long-half-life drugs (12 to 36 hours), such as chlorpropamide, accumulate in the body and are very likely to cause hypoglycemia. In addition, since most sulfonylurea drugs are metabolized in the liver and excreted in the kidney, they should be used with caution in patients with hepatic and renal impairment.
비구아니드계 약물로는 메트포르민 등이 있으며, 작용기전은 정확하진 않지만 췌장에서 인슐린 분비를 증가시키는 작용은 없는 것으로 밝혀졌으며, 간에서의 포도당 신생합성을 감소시킨다. 비구아니드계 약물은 설포닐우레아계 약물보다 혈당강하효과가 약한 반면에, 저혈당을 일으킬 가능성도 낮다. 그러나 소화기계 부작용의 발생빈도가 높아 치료초기에 오심, 구토, 설사, 발진 등이 나타나며, 락트산혈증(lactic acidosis)을 유발하여 생명을 위협하는 치명적인 부작용을 일으키므로, 현재 미국에서는 실험용 약제로만 사용하고 있다. 티아졸리딘디온계 약물은 최근에 개발된 것으로 인슐린 저항성을 개선시키는 효과가 있다.Metformin, a bicyclic aniline drug, has been shown to have no action to increase insulin secretion in the pancreas, though its mechanism of action is not accurate, and it reduces glucose synthesis in the liver. BG analogue drugs have lower blood glucose lowering effects than sulfonylurea drugs, but are less likely to cause hypoglycemia. However, the incidence of gastrointestinal adverse events is high, and nausea, vomiting, diarrhea, and rash appear at the beginning of treatment, and lactic acidosis is caused to cause life-threatening fatal side effects. have. Thiazolidinedione drugs have recently been developed and have the effect of improving insulin resistance.
그외에도 탄수화물 섭취 후 탄수화물의 소화를 방해하여 혈당의 상승을 방해하는 아카보스(acarbose) 계통의 약물이 있다. 아카보스 약물은 알파-글루코아밀라제 억제제로 가역적으로 알파-D-글리코시다제 활성을 억제시키며, 주로 소장 세포의 점막에 존재하는 말타제의 활성을 억제시키는 것으로 알려져 있다. 그러나 실제로 아카보스는 말토즈 분해를 억제시키는 효과는 약하고 오히려 설탕의 분해를 강력하게 억제하는 것으로 알려져 있다.In addition, there are acarbose-based drugs that interfere with the digestion of carbohydrates after ingestion of carbohydrates, thereby hindering the rise of blood sugar. The acarbose drug reversibly inhibits alpha-D-glycosidase activity as an alpha-glucoamylase inhibitor and is known to inhibit the activity of maltase present in the mucosa of small intestinal cells. However, it is known that acarbose has a weak inhibitory effect on maltose degradation and strongly inhibits the decomposition of sugar.
한편, 현재 사용되고 있는 한방제제는 당뇨병의 삼소에 따라 각각 다르게 처방되어 지고 있다. 폐장에 열이 있어서 혀가 붉고 갈증이 심한 상소에는 폐장의 열을 내려주고(淸肺熱), 비장을 습(濕)하지 않고 자윤(滋潤)시키는 인삼백호탕(석고, 지모, 인삼, 감초), 전씨백출탕(건갈근, 인삼, 백출, 백복령, 목향, 곽향, 감초) 및 강심탕(降心湯) 등을 처방한다.Meanwhile, currently used herbal preparations are prescribed differently according to the place of diabetes. Ginseng Baekhotang (gypsum, radish, ginseng, licorice), which has a fever in the lungs and has a red tongue and a severe thirst, releases the heat of the lungs (淸 肺 熱), does not sweat the spleen, , Gwangseong Baekutang (ganggangguk, ginseng, Baekwol, Baekbokryeong, Mokhyang, Gwacheon, licorice) and Kangsimang (降 心 汤) prescribe.
위에 열이 있어서 소화가 안되고 대변이 굳어 소변을 자주 보지만 시원하지 않은 중소에는 조위승기탕(대황, 망초, 감초), 동의보감에 수재된 생진감로음(석고, 황백, 황기, 지모, 서홍화, 시호 등) 및 순기산(順氣散)을 처방한다.There is heat on the stomach, and the stool is stiff and the stool is stiff. However, the stomach is not always cool. Etc.) and pure ki (prescription).
신에 열이 있어서 신수(腎水)가 부족하고 진액(津液)이 마르며 갈증은 덜하지만 하초(下焦)가 냉해지는 하소에는 육미지황환(숙지황, 산약, 백복령, 오미자, 택사), 신기환 등을 처방한다.There is a lot of heat in the gods, so there is a lack of renal water, and the juice is dry and the thirst less. However, Prescribe.
그러나, 당뇨병의 발병시에는 상소, 중소, 하소가 각각 따로 발병할 수도 있으나, 대부분의 당뇨병 환자의 경우에는 이들 삼소가 한꺼번에 발병한다. 따라서, 통상적으로 사용되고 있는 상기와 같은 한방제제로는 삼소가 한꺼번에 발병한 당뇨병환자를 효과적으로 치료할 수 없는 경우가 대부분이다.However, when diabetes develops, appeal, small size, and calcination may occur separately, but in most diabetic patients, these three diseases occur at the same time. Therefore, most of the commonly used herbal preparations can not effectively treat diabetes mellitus suffering from the same disease.
또한, 인슐린 저항성을 감소시키고, 인슐린 분비를 증가시키며 탄수화물의 소화를 방해하면 당뇨병을 호전시킬 수 있고, 엄격하게 혈당조절을 하면 당뇨병성 합병증의 발생을 예방하거나 지연시킬 수 있다고 알려져 있으나, 제2형 당뇨병의 치료에 효과적인 약제들은 엄격한 혈당조절이나 당뇨병의 합병증을 예방하는데 부족한 점이 많아 새로운 치료제의 개발이 요구되고 있다.In addition, it is known that reducing insulin resistance, increasing insulin secretion, inhibiting carbohydrate digestion can improve diabetes, and strictly controlling blood glucose can prevent or delay the occurrence of diabetic complications. However, Drugs that are effective in the treatment of diabetes are lacking in strict blood sugar control and prevention of diabetic complications, and development of new therapeutic agents is required.
이에 본 발명자들은 생약재에서 인슐린 분비를 증가시키는 물질을 연구하던 중, 천화분, 갈근, 생지황, 오미자, 감초, 의이인, 대추의 추출물에서 인슐린 작용을 향상시키는 효과가 있음을 확인하고 본 발명을 완성하였다.Accordingly, the inventors of the present invention completed the present invention upon confirming that it has an effect of enhancing insulin action in extracts of chrysanthemum powder, Puerariae radix, Bacillus subtilis, Omija, licorice root, Waiin, jujube and jujube while studying substances which increase insulin secretion in herbal medicines.
한편, 한방 추출물을 제조하기 위한 종래의 방법으로는 등록특허 제10-0930122호의 밤꽃 유래의 천연 식물 추출물을 포함하는 한방 화장용조성물 및 그의 제조방법과, 등록특허 제10-1145498호의 천연한방추출물을 포함하는 바디워시제조방법 및 그 바디워시조성물에서와 같은 종래기술에서 한방생약재의 추출에 사용되는 방법으로는 증류, 용매추출, 막 분리, 결정화, 증발 및 흡착법 등이 있으며, 이중 가장 많이 채용하는 증류법은 각 물질간의 휘발도의 차이를 이용하는 방법이고, 용매추출법은 용해도의 차이, 막 분리는 투과도의 차이를 이용하는 분리방법이 있다.As a conventional method for preparing the herbal extract, a herbal cosmetic composition comprising a natural plant extract derived from chestnut flower of Patent No. 10-0930122, a method for producing the composition, and a natural herb extract of Registration No. 10-1145498 The methods used for the extraction of herbal medicines in the prior art, such as in the bodywash manufacturing method and its body care compositions, include distillation, solvent extraction, membrane separation, crystallization, evaporation and adsorption, Is a method of utilizing the difference in volatility between the respective materials, and in the solvent extraction method, there is a separation method that utilizes the difference in solubility and the difference in the permeability of the membrane.
증류법은 증기압이 비슷하거나 비휘발성인 물질을 분리하는 경우에 채용되고 있으며, 많은 에너지를 필요로 한다. 이 방법은 한방생약재와 같이 열분해 및 열변성이 있는 물질은 고온으로의 공정화가 어렵다는 단점이 있으며, 용매추출법은 독성이 강한 용매를 다량으로 사용함으로써 추출비용이 많이 들고, 원하는 순도를 얻기 위해서는 후처리가 필요하며, 막 분리법은 농도의 분극화로 인한 고순도의 추출물을 얻기 어렵다는 단점이 있다.Distillation is employed in the case of separating substances with similar vapor pressures or nonvolatiles and requires a lot of energy. This method is disadvantageous in that it is difficult to process pyrolysis and heat denatured materials such as herbal medicines at high temperature, and the solvent extraction method has a problem in that the extraction cost is high by using a large amount of toxic solvent, And the membrane separation method is disadvantageous in that it is difficult to obtain a high purity extract due to polarization polarization.
이에 본 발명은 상기한 문제점을 일소하기 위해 창안한 것으로서, CO₂또는 N₂캐리어 기체를 이용하여 추출물을 농축하여 고농도의 시럽이나 젤리 형태로 농축함으로써 수득된 한방생약재 추출물이 비타민, 아미노산 등을 조금도 파괴하지 않고, 효소활성, 낮은 산소용해도, 높은 점도로 인한 산화방지 효과를 극대화할 수 있을 뿐만 아니라, 물성, 맛, 향, 색도를 변화 없이 추출 후 대기 중에서도 아주 천천히 변화는 특성을 가짐으로써 혈당 방지효과가 향상되도록 한 초임계 추출법에 의한 한방차 추출조성물 및 이의 제조방법을 제공함에 주안점을 두고 그 기술적 과제로서 완성한 것이다.SUMMARY OF THE INVENTION Accordingly, the present invention was conceived to solve the above-mentioned problems, and it is an object of the present invention to provide a herbal medicine extract obtained by concentrating an extract using a CO 2 or N 2 carrier gas and concentrating it in a high concentration syrup or jelly form, It is possible to maximize the antioxidative effect due to enzyme activity, low oxygen solubility and high viscosity, and to have a very slow change characteristic in the atmosphere after extraction without changing physical properties, taste, incense and color, And a method for producing the same. The present invention has been accomplished on the basis of the technical object of the present invention.
위 기술적 과제를 달성하기 위한 본 발명은 천화분 10∼20중량%, 갈근 5∼10중량%, 생지황 5∼10중량%, 오미자 5∼10중량%, 감초 5∼10중량%, 의이인 20∼50중량%, 대추 5∼10중량%를 포함하여 이루어짐을 특징으로 하는 한방차 조성물로 된 것이다.In order to accomplish the above object, the present invention provides a method for producing a starch, comprising the steps of: 10 to 20 wt% of silkworm, 5 to 10 wt% of Puerariae radix, 5 to 10 wt% of raw persimmon, 5 to 10 wt% %, And jujube of 5 to 10% by weight, based on the total weight of the composition.
또한, 본 발명은 천화분 10∼20중량%, 갈근 5∼10중량%, 생지황 5∼10중량%, 오미자 5∼10중량%, 감초 5∼10중량%, 의이인 20∼50중량%, 대추 5∼10중량%의 중량비로 배합된 한방생약재 분쇄물을 CO₂또는 N₂캐리어 기체를 이용한 초임계 추출법으로 추출 및 농축하여 제조됨을 특징으로 하는 초임계 추출법에 의한 한방차 추출조성물 제조방법으로 된 것이다.The present invention also relates to a method for preparing a fermented soybean paste comprising 10 to 20% by weight of a silkworm powder, 5 to 10% by weight of a gypsum powder, 5 to 10% by weight of raw persimmon, 5 to 10% And 10% by weight based on the total weight of the herbal composition, and extracting and concentrating the pulverized herb medicine with a supercritical extraction method using CO2 or N2 carrier gas.
상기한 본 발명의 한방차용 조성물 및 초임계 추출법에 의한 한방차 추출조성물 제조방법과 이를 이용한 탄산음료 및 건강음료 제조방법은 한방생약재 추출물이 비타민, 아미노산 등을 조금도 파괴하지 않고, 효소활성, 낮은 산소용해도, 높은 점도로 인한 산화방지 효과를 극대화할 수 있을 뿐만 아니라, 물성, 맛, 향, 색도를 변화 없이 추출 후 대기 중에서도 아주 천천히 변화는 특성을 가짐으로써 혈당조절효과 및 항암효과가 월등히 향상되는 효과가 있다.The method for preparing a herbal tea extract composition according to the present invention and the method for preparing a carbonated beverage and a health drink using the herbal composition and the supercritical extraction method according to the present invention are characterized in that the herbal medicine extract does not destroy any vitamins and amino acids, It is possible to maximize the antioxidant effect due to solubility and high viscosity, and to change slowly even in the atmosphere after extraction without changing the physical properties, taste, flavor, and color, so that the blood glucose controlling effect and the anticancer effect are greatly improved .
도 1은 본 발명에 의한 한방차 추출조성물의 제조 공정도
도 2는 본 발명에 의한 추출농축기의 개략도
도 3은 본 발명에 의한 추출농축온도의 예상분서 데이터 예시도
도 4는 본 발명에 의한 캐리어 기체 농축기와 기존의 감압농축기와의 분리능 비교실험 데이터 예시도
도 5는 본 발명에 의한 추출농축기내의 온도와 몰분율의 상태도
도 6은 본 발명에 의한 추출농축기의 내부 온도변화 상태도Fig. 1 is a view showing a process for producing a herbal tea extract composition according to the present invention
2 is a schematic view of an extractive concentrator according to the present invention
FIG. 3 is a graph showing an example of expected supernatant data of the extraction concentration temperature according to the present invention
4 is a graph showing an example of comparative experimental data of a carrier gas concentrator according to the present invention and a conventional separator
5 is a graph showing the state of temperature and molar fraction in the extractive concentrator according to the present invention
FIG. 6 is a graph showing the internal temperature change state of the extraction concentrator according to the present invention
본 발명의 한방차용 조성물 및 초임계 추출법에 의한 한방차 추출조성물 제조방법과 이를 이용한 탄산음료 및 건강음료 제조방법은 첨부된 각 도면에 의거 보다 상세히 설명하면 하기와 같다.The method for preparing the herbal composition for the herbal tea of the present invention and the method for preparing the herbal tea extract composition by the supercritical extraction method and the method of manufacturing the carbonated beverage and the health drink using the same will be described in more detail with reference to the accompanying drawings.
도 1 내지 도 6을 참조하여 보면 본 발명에 의한 한방차용 조성물은 천화분, 갈근, 생지황, 오미자, 감초, 의이인, 대추를 포함하여 이루어지며, 초임계 추출법에 의한 한방차 추출조성물 제조방법은 상기 조성물을 배합하여 분쇄하여 된 한방생약재분쇄물을 CO₂또는 N₂캐리어 기체를 이용하여 추출 및 농축하여 제조가 이루어진다.
1 to 6, the method for preparing a herbal tea extract composition by supercritical extraction comprises the steps of: mixing the composition of the present invention Is extracted and concentrated by using a CO 2 or N 2 carrier gas to prepare a pulverized herbal medicine pulverized product.
상술된 한방생약재들의 효능을 설명하면 다음과 같다.The efficacy of the herbal medicines described above is as follows.
천화분(天花粉, Trichosanthis Radix)은 다년생 덩굴성 초본으로써, 하늘타리(Trichosanthes kirilowii Maximowicz) 또는 노랑하늘타리(Trichosanthes kirilowii Maximowicz var. japonica Kitamura(박과 Cucurbitaceae))의 피층을 벗긴 뿌리이다. 성분은 다량의 전분, 스테로이드(β-D-글루코피라노실-스티그마스트-7-엔-3β-올), 트리테르페노이드(3β,24,25-트리하이드록시큐커빗-5-엔-11-one-큐커비타신 B, D, 23,24-다이하이드록시큐커비타신 B, D), 시트룰린, β-아미노뷰티르산, 트리초산틱산(trichosantic acid) 등을 포함한다. 효능으로는 땀띠, 습진, 부스럼에 효과가 있으며, 씨앗을 다려 마시면 기침, 천식을 다스릴 수 있고, 혈당을 내려주며, 갈증을 멎게 해주는 효과가 있다.Trichosanthis Radix is a perennial vine herbaceous roots that have been peeled off from Trichosanthes kirilowii Maximowicz or Trichosanthes kirilowii Maximowicz var. Japonica Kitamura (bark and Cucurbitaceae). Ingredients include a large amount of starch, steroids (? -D-glucopyranosyl-stigmast-7-en-3β-ol), triterpenoids (3β, 24,25-trihydroxycucurbit- di-hydroxycucurbitacin B, D), citrulline,? -aminobutyrate, trichosantic acid, and the like. Effective for fever, eczema, and swelling. Seeds can be used to cough, asthma can be controlled, blood sugar is reduced, and has the effect of stopping the thirst.
갈근(葛根, Puerariae Radix)은 콩과(Leguminosae)에 속하는 칡(Pueraria thunb.)의 뿌리를 코르크껍질을 제거하고 절편으로 하여 만든 것으로, 다이드진 (Daidzin), 푸에라리안(Puerarian), 전분등이 함유되어 있다. [신농본초경]에는 소갈, 온몸의 열증, 구토, 여러 가지 마비를 다스리고 음기(陰氣)를 일으켜 여러 가지 독을 해독한다고 기재되어 있으며, [명의별록]에는 소갈과 추위에 상한 것과 더위에 지친 것을 치료한다고 기재되어 있고, 비위의 양기(陽氣)를 자극하여 상승시키는 작용이 있다.Puerariae Radix is made by cutting off the roots of Pueraria thunb. Belonging to Leguminosae and cutting off the cork. Daidzin, Puerarian, starch And so on. [Divine Maternity] states that it controls poisoning, fever of the whole body, vomiting, paralysis, causing poisoning, and detoxifying various poison. It is said to cure, and there is an action to stimulate and lift up the nasal mucous membrane (sun).
생지황(生地黃, Rehmanniae Radix)은 현삼과(Scrophulariaceae)식물인 지황 (Rehmannia glutinosa Libosch.)의 근경으로, 주성분으로는 카탈폴(Catalpol), 베르바스코스 만니톨(Verbascose mannitol), 글루코스(Glucose), 마니노트리오스(Maninotriose), 비타민 A(Vitamin A)를 포함하고 있다. 생지황은 성분이 차고 맛이 달며 독이 없고 모든 열을 풀어주고 피를 깨뜨리며, 신음을 보하고 정(精)과 혈을 북돋아 주며, 혈증(血症)을 다스리는데 쓰인다.Rehmanniae radix is a rhizome of Rehmannia glutinosa Libosch. Scrophulariaceae plant. Its main components are Catalpol, Verbascose mannitol, Glucose, Mannotriose, and vitamin A (vitamin A). It is cold, flavorless, poisonous, free of all heat, breaks blood, moans, cheeks and blood, and is used to control blood (blood).
오미자(五味子, Schizandrae Fructus)는 낙엽 활엽 덩굴나무로 잎은 어긋나고 난형(卵形) 또는 도란형(倒卵形)이며 끝은 급히 뾰족하고 톱니가 있으며 뒷면 맥상에 다소 털이 있다. 꽃은 홍백색으로 6~7월에 피며 자웅이주이다. 과실은 식용으로 쓰이고 가지 끝에 이삭모양으로 늘어지며 8~9월에 붉게 익는다. 과실을 오미자(오매자), 북오미자(Schizandrae Fructus)라고 한다. 표고 200~1,600m 지리산, 전북, 강원도가 주산지이며 충남, 충북을 제외한 전국에 야생하고, 지리적으로 일본, 사할린, 만주, 중국에 분포한다. 과실에는 시잔드롤(Schizandrol), 시잔드린 (Schizandrin) A, B, C, 안질로일고미신(angeloylgomisin) O, P, 에피고미신 (epigomisin), 프레고모이신(pregomoisin), 데옥시시잔드린(Deoxyschizandrin) 등을 함유한다. 오미자는 오래전부터 수렴, 자양, 강장, 진해약, 해주독, 목마름, 수렴고삽, 익기생진, 보신염심 등의 약효를 가져 생약원료로 한방에서 사용해오던 재료이며, 오미자주의 원료로 오래전부터 사용하여 체내 섭취에 따른 인체 안정성이 이미 확인되어 있다.Schizandrae Fructus is a deciduous broad-leaved vine, with leaves alternating with ovate or obovate, with sharp tips, sharp teeth, and slightly hairs on the back side. The flower is reddish white, bloomed in June-July, and it is migratory. Fruit is used for food, hangs in the shape of a spike at the end of the branch, and ripens red from August to September. The fruit is called Schizandrae Fructus and Schizandrae Fructus. 200 ~ 1,600 m above sea level. It is the main province of Jirisan, Jeonbuk and Gangwon provinces. It is wild throughout the country except Chungnam and Chungbuk, and is distributed geographically in Japan, Sakhalin, Manchuria and China. Fruits include Schizandrol, Schizandrin A, B, C, angeloylgomisin O, P, epigomisin, pregomoisin, deoxyschizandrin ) And the like. Omija has long been used as a raw material for medicinal herbs because of its medicinal properties such as astringency, nourishment, tenderness, astringency, ginger poison, thirst, astringency, Human stability due to ingestion has already been confirmed.
감초(甘草, Glycyrrhizae Radix)는 쌍떡잎식물 장미목 콩과의 여러해살이풀로, 성분이 따뜻하고 맛이 달며 여러 가지 극성약이나 독성약에 대한 길항작용을 하여 극약이나 독약으로 인한 약물중독을 치료하고, 세균으로 인한 독에도 중화작용 및 해독작용을 한다. 또한, 부신피질호르몬(附腎皮質)처럼 조정작용도 있어 급박한 증상을 푸는 것으로 근육의 긴장으로 인한 동통이나 신경의 긴장을 풀어주는 작용을 하며, 글리시리진(Glycyrrhizin)이 항알러지 작용을 하며, 위궤양, 십이지장궤양에도 효과가 크다. 또한, 탈콜레스테롤 작용이 있어 동맥경화를 예방하고, 유독물질을 해독하는 작용을 하므로 간장의 기능을 강화시킨다. 이 밖에 늑막염과 폐결핵에도 뚜렷한 치료 효과를 보였고, 뇌하수체전엽기능부전증, 에디슨병, 유행성 간염, 기관지천식, 피부염(두드러기, 습진, 여드름, 주근깨 등), 학질, 동상, 손발이 튼데 등 여러 질병에 뚜렷한 치료효과가 있다.Licorice (Glycyrrhizae Radix) is a perennial herb with rosemary roots of dicotyledonous plants. Its ingredients are warm and tasty. It antagonizes various polar drugs and toxic drugs and treats poisoning caused by poison or poison. It also neutralizes and detoxifies poison caused by. In addition, like corticosteroids (补 Renal Cortical), such as adjustment to work to release the symptoms of tension and muscles to relieve pain and nervous tension, Glycyrrhizin (Glycyrrhizin) and anti-allergic action, gastric ulcer , And duodenal ulcers. In addition, decholesterol action to prevent arteriosclerosis, toxic substances to detoxify the function of the liver is strengthened. In addition, there was a clear therapeutic effect on pleural inflammation and pulmonary tuberculosis, and there was a clear effect on pituitary insufficiency, Edison's disease, epidemic hepatitis, bronchial asthma, dermatitis (urticaria, eczema, acne and freckles), schizophrenia, bronchitis, Therapeutic effect.
의이인(薏苡仁, Cocicis Semen)은 벼과(Gramineae)의 율무의 종피(種皮)를 제거한 성숙한 종자를 말하며, 주요성분으로는 단백질, 지방, 탄수화물, 전분, 아미노산, 비타민 B1, 코익솔(coixol), 코익세노라이드(coixenolide) 등이 포함되어 있다. 한방에서는 소염, 배농, 이뇨 및 진통제로 사용하며, 신체의 통증, 어깨가 아프고 살결이 거칠어지는데, 또한 부종이나 사마귀 제거에도 사용하고, 폐결핵 환자와 늑막염 환자의 강장제로도 쓰인다. 민간에서는 열매 자체를 약용으로 하고 있으며, 이와 비슷한 염주의 열매도 같이 사용한다.Cocicis Semen is a mature seed from which the seed coat of Gramineae has been removed and its main components are proteins, fats, carbohydrates, starch, amino acids, vitamin B1, coixol, Coixenolide, and the like. It is used for inflammation, drainage, diuretic and analgesic in oriental medicine. It is used for body pain, shoulder pain and roughness. It is also used for edema and wart removal. It is also used as a tonic for patients with pulmonary tuberculosis and pleurisy. In the private sector, the fruit itself is used medicinally, and the fruit of similar roses is also used.
대추는 갈매나무과(Rhamnace)의 Zizyphus 속낙엽 활엽 향목의 열매로서 현재40여종과 400여종의 변종이 있는 것으로 알려져 있는데 원산지는 북아프리카와 서유럽이며 주산지는 중국이다. 잎은 타원형이며 매끄럽고 세 개의 잎맥이 뚜렷하고 타원형의 열매를 맺는데 껍질이 얇고 녹색을 띠나 익으면서 적갈색으로 변화된다.Jujube is a foliage of deciduous broad-leaved fragrant Zizyphus in Rhamnace (Rhamnace). It is known that there are about 40 varieties and 400 varieties. Origin is North Africa and Western Europe and its main origin is China. Leaves are elliptical, smooth, and three veins are distinct. They are elliptical, with thin shells, green, and reddish brown.
과육은 향기가 별로 없으며 단맛이 강하고 산미가 있어 상쾌한 느낌을 준다. 대추는 껍질이 적색을 띠고 있어 우리나라 전래의 길·흉사 예식에 올려졌으며 생식 및 요리를 통해 식용되고 있으며 생대추는 저장성이 낮기 때문에 주로 건조하여 사용하고 있다. 예로부터 대추는 한방에서 감초처럼 감미를 내기 위하여 첨가되는 경우가 많았으며, 그 자체로도 위경련. 불면증. 소화불량, 대장하혈, 청혈, 지각과민증 등의 증상을 개선시키는 효과가 있어 약용으로 사용되었다.The pulp has no fragrance, and has a strong sweetness and acidity, giving a refreshing feeling. The jujube has a red color and has been put on the road and the ceremony ceremony of Korea. It is edible through reproduction and cooking, and the biodegradation is mainly used because it is low in storage stability. From a long time, jujube has often been added to sweeten the flavor of liquorice in one room. insomnia. It was used for medicinal purposes because it had the effect of improving symptoms such as indigestion, colonic hemorrhage, cough, and hypersensitivity.
대추의 약용성분으로는 각종 sterols, alkaloids, saponins, vitamins, 세로토닌(serotonin), 유기산, 지방산류, 폴리페놀, 히드록시메틸푸프푸랄, flavonoids 및 amino산류 등이 보고되어 있다. 그리고 대추는 수 천년동안 한방에서 생약으로 소화 완화제, 강장약으로 사용되어 왔고, 민간에선 잘 익은 대추를 말렸다가 달여 먹으면 열을 내리게 하고 변을 묽게 하여 변비를 없애며 기침도 멎게 하는 것으로 알려져 있으며, 생식하면 각성작용이 있고 볶은 것은 최면작용이 있다고 하였다. 대추는 갖가지 독을 해독 중화하고 몸의 염증을 없애주며 허약한 체질을 튼튼하게 해주는 효과가 높아 한방에서는 으뜸가는 보약의 하나로 여겨왔으며 대추는 오늘날과 같이 공해독이 범람하고 인스턴트식품이 넘쳐나는 시대에 건강을 지키고 우리민족 고유의 입맛을 되찾는 데에 매우 적절한 식품이라고 할수 있겠다.As a medicinal component of jujube, various sterols, alkaloids, saponins, vitamins, serotonin, organic acids, fatty acids, polyphenols, hydroxymethylpuppural, flavonoids and amino acids have been reported. And the jujube has been used as a digestive emollient and tonic for many thousands of years as a herbal medicine. In the private sector, it has been known to dry the ripe jujube, and when it eats for a few months, it eats heat and dilutes the stool to eliminate constipation and stop coughing. If you have an arousal action and roasted, hypnotic action is said. The jujube has been considered as one of the top preservatives in the oriental medicine because it neutralizes all kinds of poison, eliminates the inflammation of the body and strengthens the fragile constitution, and the jujube has been regarded as one of the most important supplements. In the era when pollution poisoning floods and over- And it is a very suitable food for keeping the taste of our nation.
대추는 자양건위, 보간, 강장, 생진안면, 약독완화 등의 많은 약효와 암세포증식 억제작용, 콜레스테롤 감소, 비혈소판 감소성 자반병 치료, 진해와 거담작용, 만성기관지염 치료 및 세균성 이질이나 급성장염의 치료, 항 알레르기 작용 근수축력 증강작용 간 보호작용 등에 대한 최근의 임상적 연구결과가 보고됨에 따라 대추의 기능적 및 치료적 중요성을 인식하게 되었다.Jujube has many medicinal effects such as nourishment, interpenetration, tonic, facial facial and poisoning, inhibition of cancer cell proliferation, reduction of cholesterol, treatment of non platelet reducing purpura, treatment of chinhae and gaejungdam, treatment of chronic bronchitis, treatment of bacterial dyslipidemia, Anti-allergic action, muscle contraction, enhancement of liver function, etc. As a result of recent clinical studies, the functional and therapeutic importance of jujube has been recognized.
대추에는 감미가 강하며 가용성 당류가 약 10∼20%함유되어 있는데 그 주된 당류는 과당 포도당 및 자당이며 다양한 맛 성분이 함유되어 있다.
Jujube is strong in sweetness and contains about 10-20% of soluble sugars. Its main sugars are fructose glucose and sucrose, and contains various flavor components.
하기에서는 대추의 기능적 및 치료적 중요성을 파악할 수 있는 실험을 통해 더욱 상세히 설명하도록 한다.
In the following, we will explain in more detail the experiment that can grasp the functional and therapeutic importance of jujube.
1. 대추 추출액의 제조 및 성분 분석
1. Preparation and composition analysis of jujube extract
가. 실험재료end. Experimental material
본 실험에 사용한 대추는 경상북도 자인에서 생산된 복조(福棗) 품종을 건조 한 것을 선별, 수세하여 대추25%와 물75%의 비율로 110∼20℃에서 3∼6시간을 증자 추출한10。Brix대추추출액을 사용하였다The jujube used in this experiment was selected and washed with dried demineralized (福 夏) varieties produced in Gyeongsangbuk-do. The jujube was extracted with a mixture of 25% jujube and 75% water at 110 ~ 20 ℃ for 3-6 hours. Jujube extract was used
나. 일반성분, 당도, pH 및 색도I. General composition, sugar content, pH and color
시료의 일반성분은 식품공학실험법에 따라 측정하였고, 당도는 굴절당도계(Atago, Japan), pH는 pH meter(Hanna, U.S.A.)로 측정하였다. 색도는 대추추출액 1 mL를 취하여 증류수로 10배 희석한 다음 0.45㎛ membrane filter로 여과한 후 이액을spectrophotometer (Pharmacia, Sweden)를 이용하여 500 ㎚에서 흡광도를 측정한 후 희석배수를 곱하였다.The general components of the samples were measured according to the food engineering experiment method, and the sugar content was measured with a refractometric meter (Atago, Japan) and the pH was measured with a pH meter (Hanna, U.S.A.). The color of the jujube extract was diluted 10 times with distilled water and filtered through a 0.45 μm membrane filter. The absorbance of the solution was measured at 500 nm using a spectrophotometer (Pharmacia, Sweden) and then multiplied by the dilution factor.
다. 아미노산All. amino acid
아미노산분석은 일정량의 시료를 6N-HCl 용액와 혼합하여 질소충진 후 110℃에서 24시간동안 가수분해한 후 50mL로 정용하였다. 이를0.45㎛ membrane filter로 여과하여 20㎕를 취하여 진공 건조하였다. 건조된 시료에 methanol : water : triethylamine (2:2:1) 용액30㎕를 첨가하여 2차 건조한 후 여기에 유도체시 약 methanol : triethylamine : H2O : phenyl isothiocyanate = 7:1:1:1, V/V)을 30 ㎕가하여 20분간 방치한 후 3차 건조하였다. methanol 30㎕를 첨가하여 다시건조하고 sodium acetate buffer(pH 6.4)로 재 용해하였다. 이를 HPLC(High performance liquid chromatography, Waters Associates Inc., U.S.A)를 사용하여 분석하였다Amino acid analysis was performed by mixing a certain amount of sample with 6N-HCl solution, filling with nitrogen, hydrolyzing at 110 ° C for 24 hours, and then diluting with 50 ml. This was filtered through a 0.45 μm membrane filter, and 20 μl of the filtrate was vacuum dried. To the dried sample, 30 ㎕ of methanol: water: triethylamine (2: 2: 1) solution was added and dried. V) was added, and the mixture was allowed to stand for 20 minutes, followed by tertiary drying. 30 μl of methanol was added, dried again and re-dissolved in sodium acetate buffer (pH 6.4). This was analyzed using HPLC (High performance liquid chromatography, Waters Associates Inc., USA)
라. 무기질la. Minerals
무기질 분석은 건식회화법으로 하였다. 즉 시료를 550℃에서 4시간동안 회화시킨 후 0.2 N HNO3 용액에 용해하여 100mL로 정용한 후 여과하였다. 분석은 ICP(Inductively coupled plasma, Jobin-Yvon Model JY 38 Plus, France)를 사용하였다.Mineral analysis was carried out by dry painting method. That is, the sample was stirred at 550 ° C. for 4 hours and then dissolved in 0.2 N HNO 3 solution, and the solution was filtered with 100 mL. For the analysis, ICP (Inductively coupled plasma, Jobin-Yvon Model JY 38 Plus, France) was used.
마. 페놀성 물질hemp. Phenolic material
페놀성물질의 분석은 Folin-Denis방법을 변형하여 실시하였다. 시료용액 0.1 mL와 2% sodium carbonate 2 mL를 혼합한 뒤 2분후 50% Folin & Ciocalteu's phenol reagent 0.1mL를 가하여 30분 동안 실온에 방치한 다음 UV-VIS spectrophotometer (Shimadzu UV-1201)을 이용하여 750 ㎚에서 흡광도를 측정하였으며 표준용액은 chlorogenic acid를 사용하였다.Analysis of the phenolic material was carried out by modifying the Folin-Denis method. 0.1 mL of the sample solution and 2 mL of 2% sodium carbonate were mixed. After 2 minutes, 0.1 mL of 50% Folin and Ciocalteu's phenol reagent was added, and the mixture was allowed to stand at room temperature for 30 minutes. Then, the mixture was treated with a UV-VIS spectrophotometer (Shimadzu UV- ㎚. The standard solution was chlorogenic acid.
바. 비 휘발성 유기산, 유리당bar. Non-volatile organic acids, free sugars
비휘발성 유기산분석은 시료를 감압 건조시키고 BF3/methanol로 methylation 시킨후 GC에 주입하였고 칼럼은 DB-FFAP(0.53㎜ㅧ30m), 칼럼온도는100℃(5min)-4℃/min-220℃(5min), 주입부 온도 230℃, 검출기FID) 온도 250℃, 운반기체는 질소(2mL/min)로 분석하였다. The column was DB-FFAP (0.53 mm ㅧ 30 m) and the column temperature was 100 캜 (5 min) -4 캜 / min-220 캜 ( 5 min), inlet temperature 230 [deg.] C, detector FID) temperature 250 [deg.] C, and carrier gas was analyzed with nitrogen (2 ml / min).
유리당은 각 시료를 혼상수지TMD-8(Sigma, U.S.A.)로 이온성물질을 제거한 다음 HPLC법으로 분석하였다. 분석기기는 HPLC(Young-In HPLC 930 pump, Korea)를 이용하고, 분리칼럼은 Rezex RNM과 RPM(7.8ㅧ300 ㎜, Phenomenex, U.S.A.), 이동상은 초순수 유속은 0.6mL/min, 칼럼온도는 75℃, 검출기는Shimadzu RID-6A를 사용하였다.
The free sugars were analyzed by HPLC method after removal of ionic substances by using TMD-8 (Sigma, USA) as a resin. Rezex RNM and RPM (7.8 ㅧ 300 mm, Phenomenex, USA) were used for the separation column, and the flow rate of ultrapure water was 0.6 mL / min for the mobile phase. The column temperature was 75 And detector was Shimadzu RID-6A.
2. 대추 추출액의 생리활성 측정
2. Measurement of physiological activity of jujube extract
가. 전자공여능 측정end. Electron donating ability measurement
대추 추출액의 전자공여 작용(Electron donating abilities, EDA)은Blois(66)의 방법을 변형하여 측정하였다. 2배 희석한 각 시료를 1.0mL에2×0-4 M의 α, α-diphenyl-β-picryl-hydrazyl(DPPH) 1.0 mL를 넣고 교반한 후 30분간 방치한 다음 517 nm에서 흡광도를 측정하였다. 전자공여 효과는 시료첨가구와 첨가하지 않은 경우의 흡광도감소율로 나타내었다.The electron donating abilities (EDA) of jujube extracts were measured by the modified method of Blois (66). 1.0 mL of 2 × 0-4 M α, α-diphenyl-β-picryl-hydrazyl (DPPH) was added to 1.0 mL of each diluted sample and allowed to stand for 30 minutes. Absorbance was measured at 517 nm . The electron donating effect was expressed by the absorbance reduction ratio when the sample was not added.
전자공여능% = (1 -(시료첨가구의흡광도)/무첨가구의흡광도) ×100Electron donating ability% = (1 - (absorbance of sample added sphere) / absorbance of no added sphere) x 100
나. Xanthine Oxidase 저해효과I. Xanthine Oxidase inhibitory effect
Xoase 활성저해 측정은 Stirpe와 Corte의 방법에 준하여 측정하였다. 즉 반응구는 0.1M potassium phosphate buffer(pH 7.5)에 xanthine 2mM을 녹인 기질액 1 mL에 효소액 0.1 mL(40 mU Xantine Oxidase)와 시료용액 0.1mL를 가하고 대조구에는 시료대신 증류수를 0.1mL를 첨가하여 37℃에서 5분간 반응시키고, 1 N HCl 1mL를 가하여 반응을 종료시킨 다음 반응액 중에 생성된 uric acid를 흡광도 292 nm에서 측정하여 다음 식으로 저해율을 구하였다.Xoase activity inhibition was measured by Stirpe and Corte method. In other words, 0.1 mL of the enzyme solution (40 mU Xantine Oxidase) and 0.1 mL of the sample solution were added to 1 mL of the substrate solution in which 2 mM of xanthine was dissolved in 0.1 M potassium phosphate buffer (pH 7.5), 0.1 mL of distilled water was added to the control sample The reaction was terminated by the addition of 1 mL of 1 N HCl, and the uric acid produced in the reaction solution was measured at 292 nm. The inhibition rate was determined by the following equation.
저해율% = (1 - 반응구의uric acid)/대조구의uric acid ×100Inhibition rate% = (1 - uric acid in the reaction) / uric acid in the control × 100
다. Tyrosinase 저해효과All. Tyrosinase inhibitory effect
Tyrosinase 활성저해 측정방법은 tyrosinase의 작용결과 생성되는 DOPA chrome을 비색법에 의해 측정하는 Yagi 등의 방법에 준하여 실시하였다. Mushroom tyrosinase(110unit/mL) 0.1mL, 기질로서 5mML-DOPA 0.2mL, 0.175 M phosphate buffer(pH 6.8) 0.2mL의 혼합액에 추출용액0.5 mL를 첨가하여 35℃, 2분간 반응시켜 반응액 중에 생성된 DOPA chrome을 475 ㎚에서 측정하여 다음 식으로 저해율을 구하였다.Tyrosinase activity inhibition assay was performed according to the method of Yagi et al., Which measures DOPA chrome produced by the action of tyrosinase by colorimetry. 0.5 mL of the extraction solution was added to a mixture of 0.1 mL of Mushroom tyrosinase (110 units / mL), 0.2 mL of 5 mM L-DOPA as a substrate and 0.2 mL of 0.175 M phosphate buffer (pH 6.8), and the mixture was reacted at 35 ° C. for 2 minutes, DOPA chrome was measured at 475 nm and the inhibition rate was calculated by the following equation.
Inhibition effect(%) = (1 - SAbs - BAbs)CAbs/ ×100Inhibition effect (%) = (1 - SAbs - BAbs) CAbs / 占 100
여기서,here,
SAbs : Absorbance at 475 nm determined with test sampleSAbs: Absorbance at 475 nm determined with test sample
BAbs : Absorbance at 475 nm determined with buffer instead of enzymeBAbs: Absorbance at 475 nm determined with buffer instead of enzyme
CAbs : Absorbance at 475 nm determined with buffer instead of test sampleCAbs: Absorbance at 475 nm determined with buffer instead of test sample
라. 금속이온 봉쇄작용la. Metal ion blocking action
금속이온 봉쇄작용은 Buege와 Aust의 방법을 변형하여 측정하였다. 1 mL 반응혼합물에 금속이온과 시료를 채워 37℃ water bath에서 1시간동안 반응시켰다. 반응이 끝나자마자 50 ㎕dibutyl hydroxy toluene(BHT) 7.2%를 시료에 가하여 산화반응을 정지시켰다. 반응혼합물을 잘 섞은 다음 2 mL TCA/TBA 시약을 가하고 다시 혼합 후 끊는 물에서 15분간 가열시켰다. 가열 후 찬물에서 식힌 후 2,000ㅧg의 속도로 15분간 원심분리 시켰다. 상징액을 531 nm에서 흡광도를 측정하였고 공시료는 시료대신에 증류수를 가하여 같은 방법으로 측정하여 저해율을 측정하였다Metal ion blocking activity was measured by varying the method of Buege and Aust. 1 mL of the reaction mixture was filled with metal ions and a sample and reacted in a water bath at 37 ° C for 1 hour. As soon as the reaction was completed, 50 μl of dibutylhydroxy toluene (BHT) was added to the sample to stop the oxidation reaction. The reaction mixture was mixed well, then 2 mL of TCA / TBA reagent was added, mixed again and heated in boiling water for 15 minutes. After heating, the mixture was cooled in cold water and centrifuged at a rate of 2,000 g for 15 minutes. The absorbance of the supernatant was measured at 531 nm and the inhibition rate was measured by the same method using distilled water instead of the sample
금속이온 봉쇄능%) = (1 - 시료첨가구의흡광도)/ 무첨가구의흡광도 ×100Metal ion blocking capacity%) = (1 - absorbance of sample added solution) / absorbance of non-added solution x 100
마. 암세포주 증식억제 효과hemp. Cancer cell proliferation inhibitory effect
(1) 세포배양(1) Cell culture
본 실험에 이용한 세포 MDA-MB-231(breast cancer, KCLB 30026), SK-MEL-31(Malignant melanoma, KCLB 30073), G361(Melanoma), A549(lung cancer, KCLB 10185)는Korean Cell Line Bank(KCLB)로부터 구입하였다. 각 세포의 배양은 10% fetal bovine serum과 100units/mL의penicillin/streptomycin을 1%를 첨가한 RPMI 1640 배지를 사용하였으며, 37℃, 5% CO₂ incubator에 적응시켜 배양하였다.Cell lines MDA-MB-231 (breast cancer, KCLB 30026), SK-MEL-31 (Malignant melanoma, KCLB 30073), G361 (Melanoma) and A549 (lung cancer, KCLB 10185) KCLB). Each cell was cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 100 units / mL penicillin / streptomycin 1%, and cultured at 37 ° C in a 5% CO 2 incubator.
(2) MTT assay(2) MTT assay
대추 추출액의 암세포주에 대한 증식 억제효과는 Charmichael 등의 방법에 따라 MTT assay를 실시하였다. 암세포 주를 96 well plate에 1ㅧ104cells/ well이 되게 180㎕ 분주하고 각 시료를 2배 희석하여 20uL 첨가한 후 37℃, 5% CO₂ 항온기에서 48시간 배양하였고 대조군은 시료와 동량의 증류수를 첨가하여 동일한 조건으로 배양하였다. 여기에 5mg/mL 농도로 제조한 MTT(N-methylthiotetrazol)용액 20 ㎕를 첨가하여 4시간 더 배양하였다. 배양종료 후 배양액을 제거하고 각 well당 DMSO 150㎕를 가하여 30분간 교반 후 ELISA reader로 550 nm에서 흡광도를 측정하여 암세포주의 성장억제효과를 측정하였다. 세포증식 억제효과는 다음과 같은 계산식으로 구하였다.The proliferation inhibitory effect of jujube extract on cancer cell lines was determined by MTT assay according to the method of Charmichael et al. The cells were cultured in a 37 ° C, 5% CO 2 incubator for 48 hours, and the control group was treated with the same amount of distilled water as the sample And cultured under the same conditions. To this was added 20 쨉 l of a solution of MTT (N-methylthiotetrazol) prepared at a concentration of 5 mg / ml and further cultured for 4 hours. After completion of the incubation, the culture medium was removed, and 150 μl of DMSO was added to each well. After stirring for 30 minutes, the absorbance at 550 nm was measured with an ELISA reader to measure the inhibitory effect of cancer cells. The inhibitory effect on cell proliferation was calculated by the following equation.
Growth inhibition effect(%) = 대조구의 흡광도-시료처리구의 흡광도/ 대조구의 흡광도 ×100
Growth inhibition effect (%) = Absorbance of control - Absorbance of sample treatment / Absorption of control × 100
3. 대추 추출액의 이화학적 성분 분석
3. Analysis of Physicochemical Components of Jujube Extract
가. 일반성분end. General component
밀가루와 대추추출액의 성분분석결과, 대추추출액은 수분함량이 90.52%, 조단백질 함량0.50%, 회분함량 0.37%, 당도는 10。Brix였으며 pH는 4.65이었다. 그리고 대추추출액의 페놀성 물질은 22.82mg%의 함량을 보였다.Contents of flour and jujube extract were 90.52% moisture content, crude protein content 0.50%, ash content 0.37%, sugar content 10.Brix and pH 4.65. The content of phenolic compounds in jujube extract was 22.82mg%.
나. 유리당, 유기산 I. Free sugar, organic acid
대추추출액의 유리당은 sucrose, fructose 및 glucose의 3종류로서 sucrose의 함량이 4,340 mg%로 가장 많았으며 glucose 3,910 mg%, fructose 1,360 mg%이었다. The free sugars of jujube extracts were sucrose, fructose and glucose. The content of sucrose was 4,340 mg%, glucose 3,910 mg% and fructose 1,360 mg%.
대추추출액의 비휘발성 유기산을 조사한 결과, levulinic acid의 함량이 295.69 mg%로 가장 많았고, malic acid,oxalic acid가 각각 36.13, 32.88 mg%로 나타났으며 citric acid, lactic acid, glutaric acid는 미량 존재하는 것으로 나타났다.The content of levulinic acid was 295.69 mg%, malic acid and oxalic acid were 36.13 and 32.88 mg%, respectively, and citric acid, lactic acid and glutaric acid were abundant in the nonvolatile organic acids of jujube extract. Respectively.
다. 무기질All. Minerals
대추추출액의 칼륨과 칼슘 함량은 12,425ppm와 314.72ppm으로 나타났다. 대추추출액은 칼륨의 함량이 가장 많았으며, 인, 마그네슘, 칼슘순이며, 철, 망간, 아연의 함량은 적게 나타났다.
The contents of potassium and calcium of jujube extract were 12,425ppm and 314.72ppm, respectively. The contents of potassium, magnesium, and calcium were the highest in jujube extract, and the contents of iron, manganese, and zinc were small.
4. 대추 추출액의 생리활성 및 암세포 증식억제효과
4. Physiological activity and proliferation inhibition effect of jujube extract
가. 전자공여능 측정end. Electron donating ability measurement
Free radical scavenger 기능은 중요한 항산화특성 요인의 하나이며 DPPH는 free radical로 항산화제와 반응시켜 항산화제의 free radical scavenger 능력을 측정할 수 있다. 그래서 본 실험에서는 free radical로 α, α'-diphenyl-β-picrylhydrazyl(DPPH)을 이용하여 대추추출액의 전자공여능을 측정하였다. 10。Brix 대추추출액은 86.50%의 높은 항산화효과를 가지며 또한 대추추출액을 증류수로 2배 희석한 5。Brix 대추추출액의 항산화효과도 70.49%로 높은 활성을 나타내어 대추추출액의 높은 항산화 효과를 확인하였다.Free radical scavenger function is one of the important antioxidant characteristics. DPPH can be measured by free radical scavenger ability of antioxidant by reacting with antioxidant as free radical. Therefore, in this experiment, the electron donating ability of jujube extract was measured using α, α'-diphenyl-β-picrylhydrazyl (DPPH) as free radical. 10.Brix jujube extract showed high antioxidative effect of 86.50% and antioxidative effect of 5.Brix jujube extract diluted twice with distilled water also showed high antioxidative effect of jujube extract.
나. Xanthine oxidase 저해I. Xanthine oxidase Inhibition
Xanthine oxidase는 생체내 퓨린대사에 관여하는 효소로서 xanthine 또는 hypoxanthine으로부터 요소를 형성하며 요소가 혈장내에 증가되면 골절에 축적되므로 통증을 동반하는 통풍을 유발할 뿐만 아니라 신장에 침착되어 신장질환을 일으키기도 한다, 10。Brix 대추추출액과 2배 희석한 5。Brix 대추추출액의 xanthine oxidase 저해효과를 측정한 결과는, 10。Brix 대추추출액은 72.78%, 5。Brix 대추추출액은 53.40%로 높은 저해효과를 나타내었다.Xanthine oxidase is an enzyme involved in purine metabolism in vivo and forms an element from xanthine or hypoxanthine. When the element is accumulated in the plasma, it accumulates in the fracture, so it causes not only painful gout but also kidney disease, 10. Inhibition effect of xanthine oxidase inhibition of Brix jujube extract and double-diluted 5.Brix jujube extract was 72.78% in juice of 10.Brix juice and 53.40% in juice of juice juice of 5.Brix juice .
다. Tyrosinase 저해All. Tyrosinase Inhibition
Melanin을 형성하는 tyrosinase 저해효과를 측정한 결과, 10。Brix 대추추출액은 22.78%의 저해효과를 나타내었고 증류수로 2배 희석한 5。Brix 대추 추출액에서는 10.43%의 저해효과를 나타내었다.The tyrosinase inhibitory effect of melanin was found to be 10.23% inhibition effect in 10Brix jujube extract and 10.43% inhibition in 5.Brix jujube diluted twice in distilled water.
라. 금속이온 봉쇄작용la. Metal ion blocking action
대추 추출액을 첨가한 oil emulsion의 금속이온 봉쇄작용은 Fe2+, Cu2+이온 binding 능력을 측정한 결과, Fe2+이온 binding 능력은 10。Brix 대추 추출액과 증류수로 2배 희석한 5。Brix 대추 추출액에서 각각 41.21%와 24.05%를 나타내었고 Cu2+이온 binding 능력에서는10。Brix 대추 추출액과 증류수로 2배 희석한 5。Brix 대추 추출액에서각각 62.65%와 36.0%로 우수한 binding 능력을 나타내었다.The Fe2 + ion binding capacity of the oil emulsion containing jujube extract was 41.21% in the 5.Brix jujube extract and in the 5.Brix jujube diluted with distilled water, respectively, as measured by Fe2 + and Cu2 + And 24.05%, respectively. In the Cu2 + ion binding ability, the binding ability was shown to be 62.65% and 36.0% in the 5.Brix jujube extract and the 5.Brix jujube diluted twice with distilled water, respectively.
마. 암세포 증식억제효과hemp. Cancer cell proliferation inhibitory effect
10。Brix 대추추출액과 증류수로 2배 희석한 5。Brix 대추추출액을 MDA- MB-231(breast cancer), SK-MEL-31(Malignant melanoma), G361(Melanoma), A549(lung cancer) 4종의 암세포주에 투여하여 각각의 암세포주 증식억제효과를 관찰였다. 10. Brix jujube extract and two-fold diluted 5.Brix jujube extract were used for MDA-MB-231 (breast cancer), SK-MEL-31 (malignant melanoma), G361 (melanoma) and A549 And the inhibitory effect of each cancer cell proliferation was observed.
MDA-MB-231(유선암세포 암세포주에 대한 증식억제 시험결과 10。Brix 대추추출액과 증류수로 2배 희석 한 5。Brix 대추추출액에서 92.95%와 91.96%의 우수한 증식억제효과를 확인하였으며 SK-MEL 31(악성피부암세포 암세포주 증식억제시험 결과에서도 역시 10。Brix 대추추출원액과 증류수로 2배 희석한 5。Brix 대추추출액에서 93.64%와 92.02%의 우수한 증식억제효과를 보였다. G361(피부암세포와 A549(폐암세포 암세포주의 경우 G361 암세포의 경우 10。Brix 대추추출액이 95.64%의 증식억제능을 보였으며 증류수로 2배희석 한 5。Brix 대추추출액은 94.70%의 우수한 증식억제효과를 나타내었다.MDA-MB-231 (proliferation inhibition test on mammary tumor cell lines) showed excellent proliferation inhibitory effect of 92.95% and 91.96% in 10.Brix jujube extract and 5.Brix jujube diluted twice with distilled water. SK-MEL 31 (In the inhibition test of malignant skin cancer cell tumor cell proliferation, the growth inhibition effect was also excellent 93.64% and 92.02% in the 5.Brix jujube extract and 2-fold diluted 5.Brix jujube extract of distilled water. A549 (In the case of lung cancer cell cancer, 10.Brix jujube extract showed 95.64% proliferation inhibitory effect in G361 cancer cells and 5.Brix jujube diluted with distilled water showed 94.70% proliferation inhibitory effect.
그리고 A549 암세포에서는10。Brix 대추추출액은 95.41%의 우수한 증식억제능을 보였으나 증류수로 2배희석 한 5。Brix 대추추출액의 경우 55.32%의 증식억제능을 보였다. 대추추출액의 암세포 증식억제 시험결과에서 대추추출물이 4종의 모든 암세포주에서 증식억제효과를 나타내는 것으로 나타났고 대추추출물이 농도의 증가에 따른 암세포주의 우수한 증식억제효과를 보임을 알 수 있었다. 이 결과로 대추추출액의 암세포주에 대한 우수한 증식억제 효과는 확인하였으나 어떠한 물질에 의한 영향인지를 확인하고 그 물질을 분리·정제하여 동물실험과 임상실험을 통한 항암성 등의 기능성확인 연구가 필요하다.
In the A549 cancer cell, the 10.Brix jujube extract showed an excellent proliferation inhibitory ability of 95.41%, whereas the 5.Brix jujube extract diluted twice with distilled water showed a proliferation inhibitory ability of 55.32%. The jujube extract inhibited the proliferation of all four cancer cell lines. The extracts of jujube showed excellent proliferation inhibitory effect of the cancer cells with increasing concentration. As a result, it was confirmed that the jujube extract's excellent proliferation inhibitory effect on the cancer cell line was confirmed. However, it is necessary to confirm the effect of the substance on the cancer cell line and isolate and purify the substance, .
상술된 한방생약재는 천화분 10∼20중량%, 갈근 5∼10중량%, 생지황 5∼10중량%, 오미자 5∼10중량%, 감초 5∼10중량%, 의이인 20∼50중량%, 대추 5∼10중량%의 중량비로 배합하여 사용한다. 이와 같은 조성비는 각각의 생약성분이 갖는 유효용량과 부작용 등을 고려하여 찾아낸 것이며, 그 비율의 범위를 벗어나는 경우에는 효과가 급격히 떨어지거나 부작용의 우려가 있다.The above-mentioned oriental medicinal herb has 10 to 20 wt% of silkworm, 5 to 10 wt% of Puerariae radix, 5 to 10 wt% of raw persimmon, 5 to 10 wt% of Omija, 5 to 10 wt% of licorice, 20 to 50 wt% 10% by weight. Such a composition ratio has been found in consideration of the effective dose and side effects of each herbal medicine component, and when the ratio is out of the range, the effect is drastically decreased or there is a fear of side effects.
상기 배합된 한방생약재는 한방차 조성물로 사용되며, 이때 CO₂또는 N₂캐리어추출기를 통해 추출 및 농축하도록 구성된다. 이때 적용되는 초임계 추출법은 저온과 단시간에 추출이 가능하여 가장 효과적인 추출방법으로서, 물질의 특성상 고체, 액체, 기체의 3가지 상태를 가지고 있는데 온도나 압력 등에 의해 3가지 성질 중 한가지로 변하게 될 때 그 3가지 성질 중 액체도 아닌 기체도 아닌 초임계 상태가 될때 추출하는 방법이다.The herbal herb medicine is used as a herbal composition, and is extracted and concentrated through a CO 2 or N 2 carrier extractor. The supercritical extraction method can be extracted at low temperature and in a short time. Therefore, it is the most effective extraction method. It has three states of solid, liquid and gas due to the nature of the material. When it changes into one of three properties by temperature or pressure Among the three properties, it is a method to extract when it becomes a supercritical state, not a liquid or a gas.
상기 초임계추출은 임계점 이상의 유체를 추출체로 사용한 추출법으로서, 초임계유체는 많은 물질에 대하여 용해성이 우수하며, 단순히 온도와 압력의 조절에 의하여 물질의 용해성을 변화시킬 수 있는 특성을 가지고 있기 때문에 분리기술의 한 분야로 사용되고 있다. 특히 CO₂는 임계온도가 31.06℃이므로 낮은 온도에서 추출이 가능하고 추출된 유효성분의 열에 의한 손상을 막을 수 있고, 공정 중 에너지 비용도 현저히 줄일 수 있는 등의 장점이 있기 때문에 초임계 유체용매로 사용된다.The supercritical extraction is an extraction method using a fluid above a critical point as an extractant. Since the supercritical fluid has excellent solubility for many materials and can change the solubility of the substance by simply controlling the temperature and pressure, It is used as a field of technology. Particularly, since CO₂ has a critical temperature of 31.06 ℃, it can be extracted at a low temperature and can prevent damage to the extracted active ingredient by heat, and it can reduce the energy cost during the process. Therefore, it is used as supercritical fluid solvent do.
상기 CO₂또는 N₂캐리어추출기를 이용한 한방차 추출조성물의 제조방법은 도 1에서와 같이 먼저 한방생약재인 천화분, 갈근, 생지황, 오미자, 감초, 의이인, 대추의 원료를 구입하고, 그 한방생약재를 40∼60℃에서 건조시킨 후, 분쇄기에서 0.1∼0.2㎝로 절단한 다음, 절단된 한방생약재를 CO₂또는 N₂캐리어추출기에 장입하여 추출하게 된다. 그리고 추출된 추출물을 병 또는 팩에 장입한 후, 40∼90℃하에서 살균 포장하여 시험검사 및 출하하게 된다. 이때 CO₂또는 N₂캐리어추출기와 동시에 사용되는 농축기는 냉각, 순환, 교반효과를 가진다.As shown in FIG. 1, the method of manufacturing the herbal tea extract composition using the CO 2 or N 2 carrier extractor comprises the steps of: (1) purchasing raw materials of herb medicine such as chrysanthemum, chrysanthemum, persimmon, After drying at 60 ° C, it is cut to 0.1 to 0.2 cm in a pulverizer, and then the cut herbal medicine is charged into a CO 2 or N 2 carrier extractor for extraction. Then, the extracted extract is packed in a bottle or pack, and sterilized and packaged at 40 to 90 ° C to be tested and shipped. At this time, the concentrator used at the same time as the CO2 or N2 carrier extractor has cooling, circulating and stirring effect.
상기와 같은 한방생약재를 추출하기 위해 사용되는 CO₂또는 N₂캐리어 기체를 이용한 추출 및 농축기술은 제품의 생산공정에서 가장 중요한 공정의 하나로서 화학공정이나 실험실에서 다양한 방법으로 이용될 수 있으며, 캐리어 기체 농축기시스템은 열에 약한 물질이나 증발점이 높은 혼합물은 담체를 이용하여 효과적으로 분리할 수 있다.The extraction and concentration technique using the CO 2 or N 2 carrier gas used for extracting the herbal medicine as described above is one of the most important processes in the production process of the product and can be used in various processes in a chemical process or a laboratory, The system can effectively separate substances with weak heat or mixtures with high evaporation points using carriers.
본 발명에서의 CO₂또는 N₂캐리어 기체를 이용한 추출 및 농축 시스템은 진공펌프 대신에 캐리어 기체를 시스템에 순환시켜 용매의 증기압을 낮춤으로써 열적으로 불안전한 화합물의 변성을 막을 수 있으며, 캐리어 기체가 시스템의 폐쇄 회로공간에서 순환함으로써 저온에서도 휘발하기 쉬운 한방생약재 추출물의 고유한 약재성분, 향기, 맛을 갖는 제품을 제조할 수 있고, 추출물의 농도를 적용 조건에 따라 조절할 수 있는 효과가 있다.The extraction and concentration system using the CO 2 or N 2 carrier gas in the present invention can prevent the modification of the thermally unstable compound by lowering the vapor pressure of the solvent by circulating the carrier gas in the system instead of the vacuum pump, By circulating in a closed circuit space, it is possible to produce a product having a unique medicinal ingredient, fragrance and taste inherent to herbal medicinal herb extracts which are easy to volatilize even at low temperatures, and the concentration of the extract can be controlled according to application conditions.
이하 도시된 도면들을 참고하여 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the drawings.
도 2는 본 발명에 의한 추출농축기의 개략도로서, 시스템의 밀폐공간에 펌프(16)를 통해 비활성인 CO₂또는 N₂를 순환시키면 열교환기(14) 내에 위치되는 농축물부분의 증기압이 낮아지고 용매를 포함하는 담체는 냉각기(12) 부분으로 이동하여 용매는 응축이 일어나고, 용기(17)에 모아진다. 응축 후 건조된 CO₂ 또는 N₂는 펌프(16)를 통하여 재순환이 이루어진다.2 is a schematic diagram of an extractor concentrator according to the present invention in which circulation of inactive CO 2 or N 2 through a
도 3은 본 발명에 의한 추출농축온도의 예상분서 데이터 예시도로서 200㎖의 물을 캐리어 기체로 사용할 경우에는 비등점의 강화효과를 나타낸다. 기체부피가 15㎥/h 일 때 56℃에서 비등점이 되었음이 관찰되었다. 실험결과, 가열온도 60℃, 기체 부피가 15㎥/h 일 때 최적의 조건으로 물을 증류할 수 있음이 확인되었다.FIG. 3 is a graph showing an expected boiling point data of the extraction condensation temperature according to the present invention. When 200 ml of water is used as a carrier gas, boiling point enhancement effect is shown. It was observed that the boiling point was 56 ° C when the gas volume was 15 m 3 / h. As a result of the experiment, it was confirmed that water can be distilled under optimum conditions when the heating temperature is 60 ° C and the gas volume is 15 m 3 / h.
도 4는 본 발명에 의한 캐리어 기체 농축기와 기존의 감압농축기와의 분리능 비교실험 데이터 예시도로서, 8㎥/h 의 낮은 기체 부피에서 감압농축이 효율적인 반면, 기체부피가 10㎥/h인 경우에는 감압증류보다 분리능이 20% 증가함을 나타낸다. 최적의 조건은 15㎥/h(기체부피) 일때 분리능 80%까지 증가하였다. 단, 최대 기체부피(20㎥/h) 일 때 응축물에 공용물질이 혼합되어 오히려 분리효율이 떨어지게 된다.4 is a graph showing comparative experimental data between a carrier gas concentrator according to the present invention and a conventional reduced pressure concentrator. As shown in FIG. 4, when the gas volume is 10 m 3 / h at a low gas volume of 8 m 3 / h, Indicating a 20% increase in resolution over reduced pressure distillation. The optimum condition was increased to 80% with 15 m3 / h (gas volume). However, when the maximum gas volume (20 m 3 / h) is used, the efficiency of the separation is lowered because the common material is mixed in the condensate.
도 5는 본 발명에 의한 추출농축기내의 온도와 몰분율의 상태도로서, 농축은 비점차가 큰 용질과 용매를 분리하는 조작이며, 증류의 스트립핑(stripping)과 비교될 수 있다. 증류는 비점차가 작은 다성분계 용액을 저비점과 고비점 물질로 정제, 탈거하는 조작이며, 이를 위하여 성분의 액상 및 기상평형 관계를 규명하여야 한다. 이를 위하여 Phase TXY 평형선도를 이용하여 증발농축과 증류조작을 비교 설명하면, 선도상의 X값은 저비점 물질의 액상 분율을 Y값은 저비점 물질의 기상 분율을 나타낸다. 분리하고자 하는 용매분율 X0, 온도 T0 용액을 용매분율 Y2, 온도 T2 증기로 가열하여 온도 T1이 되어 Reverse Bar Scale식에 따라 (X0-X1)/(Y1-X1) 비율이 증기가 되어 증발하고 나머지는 액상으로 기액평형을 이룬다. 이때, 액상의 용매분율은 X1이 되어 용질은 농축되고, 기상의 용매분율은 Y1이 되어 용매는 정제된다. 이렇게 증류탑은 복수 평형단을 저온액상과 고온기상이 역방향으로 접촉하며 증발응축을 반복하여 비점물질의 농축(탈거)과 저비점 물질의 정제를 수행한다.FIG. 5 is a view showing the temperature and the mole fraction in the extracting concentrator according to the present invention. The concentration is an operation for separating the solute and the solvent having a relatively large proportion, and can be compared with the stripping of the distillation. Distillation is an operation to purify and remove a low-boiling, multi-component solution with a low boiling point and a high boiling point material. For this purpose, the liquid phase and vapor phase equilibrium relationship of the components should be determined. The X value on the line represents the liquid fraction of the low boiling point material, and the Y value represents the gas phase fraction of the low boiling point material. (X0-X1) / (Y1-X1) ratio is vaporized according to the reverse bar scaling formula, and the remaining portion is evaporated by heating the solvent fraction X0, temperature T0 solution to be separated by the solvent fraction Y2 and temperature T2 vapor, Liquid equilibrium. At this time, the solvent fraction of the liquid phase becomes X1, the solute is concentrated, the solvent fraction of the gas phase becomes Y1, and the solvent is purified. In this way, the distillation column has a plurality of equilibrium stages in which the low-temperature liquid phase and the high-temperature gase-phase are contacted in opposite directions and the evaporation condensation is repeated to concentrate (remove) the boiling point material and purify the low boiling point material.
도 6은 본 발명에 의한 추출농축기의 내부 온도변화 상태도로서, 작동 후 20분 경과 후 농축물의 온도가 일정하게 유지되어 2ℓ/h의 용매증발량을 나타내었으며, 2시간 후 농축물의 상태가 거의 시럽 형태로 변하여 온도가 조금 상승하기 시작하였다. 같은 조건에서 감압 농축하였을 경우 400mbar에서 농축물의 끓음현상 때문에 더 이상 감압할 수 없었으며, 1.2ℓ/h의 용매증발량을 나타내어 캐리어 기체 농축기가 증발량 측면에서 60%의 효율이었다.FIG. 6 is a state diagram showing the internal temperature change of the extracting concentrator according to the present invention. The concentration of the concentrate was maintained at a constant level after 20 minutes of operation and showed a solvent evaporation rate of 2 L / h. After 2 hours, And the temperature slightly started to rise. Under the same conditions, it was not able to be decompressed any more because of the boiling phenomenon of the concentrate at 400 mbar, and the evaporation amount of the solvent was 1.2 l / h, and the efficiency of the carrier gas concentrator was 60% in terms of evaporation amount.
본 발명에서 사용하는 추출농축기는 한방 생약재를 주원료로 하여 용매(에탄올, 물)를 넣고, 일정온도와 압력으로 가열하는 장치이며, 추출되어 나오는 가용성 액체를 추출액이라 한다. 또한 추출되어진 액을 필요에 따라 농도를 높이기 위해 상압 또는 감압하여 일정한 온도를 유지하여 증발되는 수분(또는 에탄올)을 냉각장치로 유입하여 회수하거나 증발 냉각하여 재순환 사용하며, 남은 잔여물(엑기스 또는 추출농축액)이 되게 하는 장치이다.The extraction concentrator used in the present invention is a device for heating a herbal medicine with a solvent (ethanol, water) as a main raw material at a constant temperature and pressure, and a soluble liquid which is extracted is called an extract. (Or ethanol) which is evaporated by keeping at a constant temperature by atmospheric pressure or decompression to increase the concentration if necessary, is recycled by evaporating and cooling by introducing the water (or ethanol) into the cooling device, and the remainder Concentrate).
본 발명에서는 한방 생약재를 CO₂나 N₂로 저온, 진공 하에서 추출하고, 추출물을 농축하여 고농도의 시럽이나 젤리형태로 농축함으로써 비타민, 아미노산 등을 조금도 파괴하지 않고, 효소활성, 낮은 산소용해도, 높은 점도로 인한 산화방지효과를 극대화할 수 있으며, 일반적으로 물성, 맛, 향, 색이 조금도 변하지 않으며, 추출 후 대기 중에서도 아주 천천히 변하며, 일반적인 추출농축과정의 특징은 다음과 같다.In the present invention, herbal medicine is extracted with CO 2 or N 2 under low temperature and vacuum, and the extract is concentrated to concentrate in high-concentration syrup or jelly form, so as not to destroy any vitamins or amino acids, And generally, the physical properties, taste, aroma and color are not changed at all, and the extract is changed very slowly even in the atmosphere after extraction. The characteristics of the general extraction concentration process are as follows.
항 미생물적, 효소적 효과는 Open Pan 증발 농축기보다 더 효과적이다. 추출농축분의 50~60%는 삼투압이 매우 강한 단당류와 산이고, 삼투압이 약한 당류의 양을 함유한 제품은 고형분의 65-70%가 되게 추출농축이 가능하다.The antimicrobial and enzymatic effects are more effective than the Open Pan evaporator. 50 to 60% of extracted concentrates are monosaccharides and acids with very strong osmotic pressure, and products containing an amount of sugars with weak osmotic pressure can be extracted and concentrated to 65 to 70% of solids.
감초 등 높은 설탕함량의 재료인 경우에는 잼, 시럽형태로 만들기 위해서 증발온도까지 가열이 가능하고, 솔잎 등은 보통 16~28%의 농축분으로 추출농축하고, 적당한 혼합물을 첨가하거나 고온살균 등의 추가적인 처리도 가능하며, 인삼 등은 Open Pan이나 진공 농축기등과 같이 농축이 가능하다. 이때 가열에 의한 Maillard 반응과 같은 품질변화도 가능하다. 이 추출농축증발공정은 감압상태, 60℃ 이하에서 수행된다. 또한, 한방생약재의 물성을 변화시키지 않고 추출농축을 위한 최소압력과 최고온도로 고추출 및 농축한다. 이때, 농축과정에서 농도와 점도가 점점 높아지므로 반응열의 냉각이 어려우므로 교반을 실시하며, 추출농축을 수행하도록 한다.In case of high sucrose content such as licorice, it can be heated up to the evaporation temperature in order to make jam or syrup. Pine needles can be extracted and concentrated by concentrating 16 ~ 28% Additional processing is possible, and ginseng can be concentrated like open pan or vacuum concentrator. At this time, the same quality change as the Maillard reaction by heating is also possible. This extraction concentration evaporation process is carried out under reduced pressure, at 60 ° C or lower. In addition, high extraction and concentration are performed at minimum pressure and maximum temperature for extractive concentration without changing the physical properties of herbal medicine. At this time, since the concentration and viscosity gradually increase during the concentration process, it is difficult to cool the reaction heat. Therefore, stirring is performed and extraction concentration is performed.
본 발명에서 사용하는 캐리어 기체 농축기는 반응로, 상측부분의 농축물 투입구는 강화유리로 제작되어 있으며, 농축기 내부를 육안으로 관찰이 가능하고, 실리콘 링으로 뚜껑을 밀폐하여 순환가스의 누출을 방지하며, 농축물의 반응성을 억제할 수 있는 소재를 사용한다. 반응로 상측 중심에는 교반기, 열교환장치, 조절박스(Control Box), 히터, 작동키, 교반조절기, 냉각기, 기체 순환펌프 조절기를 부착되어 모든 공정이 자동화되어 비전문인도 손쉽게 조작할 수 있도록 한다. 분리기는 농축물의 용매를 회수하는 장치로서 분리기 측면부분에는 유리관을설치하여 용매수위를 쉽게 측정 가능하도록 하며, 하단부에 설치된 밸브를 통하여 회수하여 재활용할 수 있도록하였다. 수조는 열교환기의 냉매를 보관하는 곳이며, 냉매의 온도를 8-15℃로 조절할 수 있으며, 냉매순환장치의 용매교환 비율을 높여서 농축효율을 높이도록 한다.The carrier gas concentrator used in the present invention is made of a reaction furnace and the concentrate inlet of the upper portion is made of tempered glass. The inside of the concentrator can be observed with the naked eye and the lid is closed with a silicone ring to prevent leakage of the circulating gas , A material capable of suppressing the reactivity of the concentrate is used. A stirrer, a heat exchanger, a control box, a heater, an operation key, a stirrer, a cooler, and a circulation pump controller are attached to the upper side of the reaction furnace, so that all the processes are automated, thereby allowing easy manipulation. The separator is a device for collecting the solvent of the concentrate. A glass tube is installed on the side of the separator to easily measure the level of the solvent, and the recovered solvent can be recovered through the valve provided at the lower end. The water tank is a place for storing the refrigerant of the heat exchanger, and the temperature of the refrigerant can be adjusted to 8-15 ° C, and the solvent exchange ratio of the refrigerant circulating device is increased to enhance the concentration efficiency.
이러한 캐리어 기체 농축기를 이용하여 성능검사를 수행한 결과(Aerosol Test) 순환 기체의 최대량으로 운전할 농축기의 공비점을 검사하기 위해 농축기 10ℓ의 증류수를 투입한 후 0.1g Fluorescein을 첨가하면 연록색의 색깔을 띈다. 반응기의 온도 50℃, 교반기 회전수 60rpm, 냉각기 온도 15℃, 기체 순환펌프 15m3/h로 하여 2시간동안 가동한 후, 분리기의 용액을 채취하여 분광광도계로 색깔의 유무로 판단하였다. 이 실험에서 채집된 용액에서 색깔이 나타나지 않아, 기체량이 최대일 때 입자의 전이가 없음을 판명되었다.(Aerosol Test) In order to examine the azeotropic point of the concentrator to operate as the maximum amount of the circulating gas, 10 liters of distilled water was added to the concentrator, and when 0.1 g of Fluorescein was added, the color became greenish . After the reactor was operated at a temperature of 50 ° C, a stirrer rotation speed of 60 rpm, a cooler temperature of 15 ° C and a gas circulation pump of 15 m 3 / h for 2 hours, the solution in the separator was sampled and judged as a color with a spectrophotometer. In this experiment, no color appeared in the collected solution, and it was found that there was no particle transition when the amount of gas was maximum.
상기와 같은 제조되는 본 발명에 의한 한방생약재 추출물은 혈당방지는 물론, 한방생약재의 유효성분인 비타민, 아미노산 등을 조금도 파괴하지 않고 효소활성, 낮은 산소용해도, 높은 점도로 인한 산화방지효과를 극대화할 수 있고, 물성, 맛, 향, 색의 변화없이 추출 후 대기 중에서도 아주 천천히 변화는 특성을 갖는다.
The herbal medicine herbal extract prepared according to the present invention as described above maximizes the antioxidant effect due to enzyme activity, low oxygen solubility, and high viscosity without any destruction of vitamins, amino acids, etc. which are active ingredients of herbal medicine And can change very slowly even in air after extraction without changes in physical properties, taste, aroma, and color.
하기에서는 실시예들을 통해 더욱 상세히 설명한다.In the following, the embodiments will be described in more detail.
<실시예 1>≪ Example 1 >
천화분 10∼20중량%, 갈근 5∼10중량%, 생지황 5∼10중량%, 오미자 5∼10중량%, 감초 5∼10중량%, 의이인 20∼50중량%, 대추 5∼10중량%를 포함한 한방생약제 분말을 혼합하고 CO₂또는 N₂캐리어 기체를 이용하여 추출 및 농축하여 한방생약재 추출물을 수득하였다.
상기 한방차 추출물 50∼80중량%와, 설탕 5∼20중량%, 구연산 0.05∼0.3중량%, 카라멜 0.005∼0.02중량%, 비타민C 0.1∼1중량%, 정제수 79∼94중량%를 혼합하여 된 탄산음료용 혼합물 20∼50중량%를 섞어서 시럽을 만든 다음, 상기 시럽을 85∼98℃에서 20∼80초간 살균하여 냉각수와 1:3.5∼4.5의 비율로 혼한한 다음 탄산가스를 주입하여 탄산음료를 제조한다.10 to 20 wt% of silkworm, 5 to 10 wt% of Puerariae radix, 5 to 10 wt% of raw persimmon, 5 to 10 wt% of Omija, 5 to 10 wt% of licorice, 20 to 50 wt% Herbal medicine powder was mixed and extracted and concentrated using a CO2 or N2 carrier gas to obtain a herbal medicine extract.
50 to 80% by weight of the herbal tea extract, 5 to 20% by weight of sugar, 0.05 to 0.3% by weight of citric acid, 0.005 to 0.02% by weight of caramel, 0.1 to 1% by weight of vitamin C and 79 to 94% The syrup is sterilized at 85 to 98 ° C for 20 to 80 seconds and mixed with the cooling water at a ratio of 1: 3.5 to 4.5. Then, the carbonic acid gas is injected into the carbonated beverage .
일실시예로서, 상기 한방 생약재 추출물을 50중량%의 양으로 포함하는 것을 특징으로 하며, 여기에 설탕 5%, 구연산 0.1%, 카라멜 0.02%, 비타민 C 0.5%의 첨가물을 혼합하고, 여기에 잔여%의 정제수를 섞어서 시럽을 만들고, 시럽을 85~98℃에서 20~180초간 살균하여 냉각수와 1:4의 비율로 혼합한 다음 탄산가스를 0.5~0.82%를 주입하여 생약재를 함유하는 한방차 추출조성 탄산음료를 제조하였다.
In one embodiment, the herbal medicinal herb extract is contained in an amount of 50% by weight, and an additive of 5% of sugar, 0.1% of citric acid, 0.02% of caramel and 0.5% of vitamin C is mixed therewith, % Of purified water to make a syrup and sterilize the syrup at 85 ~ 98 ℃ for 20 ~ 180 seconds, mix with cooling water at a ratio of 1: 4, then inject 0.5 ~ 0.82% carbon dioxide gas, Composition carbonated beverages were prepared.
(시험예 : 혈당 방지 및 발모효과 측정)(Test Example: Prevention of Blood Sugar and Measurement of Hair Growth Effect)
혈당이 있는 대상자 50명을 선정하여 상기 실시예 1에서 수득된 추출액을 이용하여 1일2회 사용하였다. Fifty subjects with blood sugar were selected and used twice a day using the extract obtained in Example 1 above.
그 결과, 증상이 있는 대상자 50명을 대상으로 1개월 이상 계속적으로 사용한 결과 48명이 혈당이 현저히 줄어들었다. 이러한 결과로부터 복용자가 혈당약을 복용하지 않고 추출물을 복용하여도 2~3일 후부터 과혈당 현상이 줄어들었고 약 20일 사용부터는 과혈당증상이 거의 중지된 것으로 관찰된 것으로 볼 때 대상자의 체질이나 직업, 생활습관에 따라 호전되는 정도에 차이가 났으나 대체적으로 만족할만한 효과를 얻을 수 있었다.
As a result, blood glucose was significantly reduced in 48 patients using 50 patients who had symptoms for more than 1 month continuously. From these results, it has been observed that the patients suffering from hyperglycemia decreased from 2 to 3 days after taking the extract without taking the blood glucose drug, and the hyperglycemia phase was almost stopped from the use of about 20 days. Therefore, the constitution, , But the effect was satisfactory in general.
<실시예 2>≪ Example 2 >
한방생물은 대구 약령시장에서 구입하여 물로 깨끗이 세척한 후, 그늘에서 건조하였다. 건조한 시료 1㎏을 70% 에탄올 10ℓ에 넣고 2시간 동안 2회 반복 추출하였다. 상기 에탄올 추출액을 꺼즈로 여과하고 2000rpm으로 원심분리하여 상등액을 회전진공 농축기에서 감압농축한 후 동결건조하여 추출 분말 시료를 만들었다.Oriental herbivores were purchased from the Daegu Yakimyeon market, washed cleanly with water, and dried in the shade. One kilogram of the dried sample was added to 10 liters of 70% ethanol and extracted twice for 2 hours. The ethanol extract solution was filtered with a filter, centrifuged at 2000 rpm, and the supernatant was concentrated under reduced pressure in a rotary vacuum concentrator and lyophilized to prepare an extract powder sample.
상기 추출 분말 시료를 물에 현탁시킨 후, 메탄올을 가하여 증량시키고 용출액의 극성을 변화시키면서 앰버라이트 XAD-4 겔(Amberlite XAD-4 gel)을 충진한 컬럼 크로마토그래피를 실시하여 물분획(Fr.1), 20% 메탄올 분획(Fr.2), 40% 메탄올 분획(Fr.3), 60% 메탄올 분획(Fr.4), 80% 메탄올 분획(Fr.5) 및 100% 메탄올 분획 (Fr.6)으로 분리한 후, 각각의 분획을 저온에서 감압농축한 후 동결, 건조하였다. 각각의 분획은 DMSO에 1㎎/㎖로 녹여 사용하였다.
The extracted powder sample was suspended in water, and then methanol was added to increase the volume. The column was packed with Amberlite XAD-4 gel (Amberlite XAD-4 gel) while varying the polarity of the eluent to obtain a water fraction ), 20% methanol fraction (Fr.2), 40% methanol fraction (Fr.3), 60% methanol fraction (Fr.4), 80% methanol fraction (Fr.5) and 100% methanol fraction ), And each fraction was concentrated under reduced pressure at low temperature, and then freeze-dried. Each fraction was dissolved in DMSO at 1 mg / ml and used.
(실험예 1 : 본 발명의 추출물이 지방세포내로의 포도당 흡수에 미치는 영향)(Experimental Example 1: Effect of the extract of the present invention on glucose uptake into fat cells)
본 발명의 추출물이 지방세포내로의 포도당 흡수에 미치는 영향을 알아보기 위하여, 하기와 같은 실험을 수행하였다.
In order to examine the effect of the extract of the present invention on glucose uptake into adipocytes, the following experiment was conducted.
1. 세포 배양1. Cell culture
실험에 사용한 3T3-L1 세포는 미국세포주은행에서 구입하였고, 1% FBS(fetal bovine serum), 젠타마이신(gentamycine, 100 units/㎖), 스트렙토마이신 (streptomycin, 100 ㎍/㎖) 등을 첨가한 DMEM(Dulbecco's modified Eagle's medium) 배지에서 배양하였다.The 3T3-L1 cells used in the experiments were purchased from a US cell line and cultured in DMEM supplemented with 1% FBS (fetal bovine serum), gentamycin (100 units / ml), streptomycin (100 μg / (Dulbecco's modified Eagle's medium).
3T3-L1 섬유아세포는 배양 3일 간격으로 배양세포 표면을 인산염 완충용액으로 씻어준 후 50㎖ 플라스크당 1㎖의 0.25% 트립신-EDTA 용액을 넣고 실온에서 1분간 처리한 다음 트립신 용액을 버리고 37℃에서 5분간 보관하여 세포를 탈착하여 계대배양하였다. 탈착된 세포는 10% FBS가 첨가된 DMEM 배양액 10㎖에 부유시킨 다음 새로운 배양용기(50㎖ culture flask)에 옮겨 1:20의 분리 비율(split ratio)로 CO₂ 배양기(37℃, 5% CO₂)에서 배양하였다.
The 3T3-L1 fibroblasts were washed with phosphate buffer solution at 3 days intervals, and then 1 ml of 0.25% trypsin-EDTA solution was added per 50 ml flask. The solution was treated at room temperature for 1 minute, and then the trypsin solution was discarded. For 5 minutes, and cells were desorbed and subcultured. The desorbed cells were suspended in 10 ml of DMEM supplemented with 10% FBS, transferred to a new culture container (50 ml culture flask) and incubated in a CO₂ incubator (37 ° C, 5% CO2) at a split ratio of 1:20, Lt; / RTI >
2. 지방세포내로의 포도당 흡수 실험2. Glucose uptake into fat cells
3T3-L1 섬유아세포를 상기 계대배양과 동일한 방법으로 완전히 채워질 (confluent) 때까지 배양하였다. 배양용기 바닥을 완전히 채운 지 2일 후에 유도분화물질인 덱사메타손(dexamethasone) 0.25μM을 넣어 3일 동안 배양한 후 2일에 한번씩 고농도 포도당 DMEM 용액으로 새로 바꾸어 주어 지방세포로 완전히 전환된 10~15일 사이에 포도당 흡수 실험을 하였다.3T3-L1 fibroblasts were cultured in the same manner as the above subculture until they were completely confluent. Two days after the bottom of the culture vessel was completely filled, 0.25 μM of dexamethasone, which is an inducible differentiation material, was added for 3 days. Then, the cells were changed into high-glucose DMEM solution every 2 days for 10-15 days Glucose uptake test.
배양용기에 있는 지방세포의 수를 세어 12 웰 플레이트의 웰을 빈 공간없이 완전히 채울 수 있도록 분주하였다. 웰 플레이트에 옮긴 지방세포를 PBS로 세척한 후 1% 소혈청알부민(bovine serum albumin)을 함유하고 있는 저농도의 포도당을 함유한 DMEM에서 12시간 이상 지난 후에 HEPES 용액에서 37℃에서 30분 동안 배양하였다. 1 μCi/㎖의 [14C]2-데옥시글루코스와 1mM 포도당을 첨가하고 22℃에서 30분 동안 배양하여 포도당의 세포내로의 흡수 정도를 14C이 세포내로 이동한 양으로 측정하였다.The number of adipocytes in the culture vessel was counted to dispense the wells of the 12-well plate so that they could be completely filled without voids. The adipocytes transferred to the well plate were washed with PBS and then cultured in HEPES solution for 30 minutes at 37 ° C in DMEM containing low concentration of glucose containing 1% bovine serum albumin for 12 hours or more . [14C] 2-deoxyglucose and 1 mM glucose were added at 1 μCi / ml and cultured at 22 ° C. for 30 minutes, and the degree of glucose uptake into the cells was measured by the amount of 14 C transferred into the cells.
비특이적인 포도당 흡수를 배제하기 위해서 글루코스 트랜스포터 4(glucose transporter 4; GLUT4)의 작용을 억제하는 사이토 B(cyto B)와 함께 배양하였을 때의 포도당 이동량을 빼고 세포내로 이동한 포도당의 양을 측정하였다.In order to exclude nonspecific glucose uptake, the amount of glucose transferred into the cell was measured by subtracting the amount of glucose transport when cultured with cyto B (glucose uptake inhibitor of glucose transporter 4 (GLUT4)) .
세포는 10mM 포도당이 함유된 PBS로 세척하고 0.5N NaOH로 세포를 분해하였다. 분해된 세포를 초산으로 중화시키고 함유된 14C의 함량을 베타 카운터(Tri-Carb 2100TR, Packard Bioscince, IL)로 측정하였다.
The cells were washed with PBS containing 10 mM glucose and the cells were digested with 0.5 N NaOH. The disrupted cells were neutralized with acetic acid and the content of contained 14C was measured with a beta counter (Tri-Carb 2100TR, Packard Bioscince, IL).
3. 본 발명의 추출 분획이 포도당 흡수에 미치는 영향3. Effect of the extract fraction of the present invention on glucose uptake
추출물의 각 분획에 인슐린 민감성 제제가 함유되어 있는 지의 여부를 조사하기 위하여, 상기 실시예에서 제조한 추출 분획을 DMSO에 1㎎/㎖로 녹인 후 이것을 PBS에 0.3 및 3㎍/㎖로 희석시켜 두 가지 농도에서 포도당 흡수를 측정하였다.In order to investigate whether each fraction of the extract contained an insulin sensitizer, the extract fraction prepared in the above Example was dissolved in DMSO at 1 mg / ml, and the diluted fraction was diluted to 0.3 and 3 μg / ml in PBS Glucose uptake was measured at branching concentrations.
3T3-L1 지방세포에 인슐린 1ng/㎖와 함께 각 분획을 넣고 1시간 동안 배양한 후에 포도당 흡수 정도를 인슐린 50ng/㎖에서의 결과와 비교하였다.3T3-L1 adipocytes were incubated with insulin at 1 ng / ml for 1 hour, and then the glucose uptake was compared with the results at 50 ng / ml insulin.
대조군으로 인슐린 0(기저), 1, 3, 5, 10, 25, 50, 75ng/㎖을 사용하였다.Insulin 0 (basal), 1, 3, 5, 10, 25, 50 and 75 ng / ml were used as controls.
모든 실험은 3번 반복하였고, 실험결과는 인슐린과 오미자 추출 분획을 모두 처리하지 않은 것의 값에 대한 비로 나타내었다.All experiments were repeated 3 times, and the results were expressed as a ratio to the value of the insulin and omija extract fractions not treated.
또한, 추출 분획의 포도당 흡수 증가 효과가 특이적으로 인슐린의 작용을 향상시켜서 나타내는 현상인지, 아니면 세포에 용제(detergent)로 비특정적으로 작용하여 포도당을 세포내로 이동하는 것인지를 조사하기 위하여 인슐린을 첨가하지 않고 추출 분획만을 넣은 상태에서 포도당을 흡수하는 정도를 측정하였다.In order to investigate whether the effect of increased glucose uptake in the extracted fraction is specifically a phenomenon exhibiting improved action of insulin or that the glucose is specifically acting as a detergent in cells to move glucose into cells, The extent of absorption of glucose was measured in the presence of only the extracted fraction without addition.
추출 분획이 인슐린의 작용에 관계없이 용제로 작용하여 세포막을 파괴시켜 포도당 흡수를 증가시키는 것을 배제하기 위해서 인슐린이 0 ng/㎖ 에서 추출 분획과 함께 포도당 흡수를 측정하였을 때, 이 값이 기저(basal) 값보다 높은 것은 포도당 흡수를 증가시킨다고 해도 인슐린 민감성 제제로서의 작용이 없는 것으로 간주하였다.In order to exclude that the extracted fraction acts as a solvent regardless of the action of insulin to increase the glucose uptake by destroying the cell membrane, when the glucose uptake is measured with the extract fraction at 0 ng / ml of insulin, ) Was considered to have no effect as an insulin sensitizer even though it increased glucose uptake.
결과는 평균ㅁ표준편차로 나타내었으며, 3T3-L1 지방세포에서 추출 분획의 대조군에 비해 포도당 흡수가 증가하는 정도는, 인슐린 1 ng/㎖만을 넣고 측정한 값과 인슐린 1 ng/㎖와 오미자 추출분획을 함께 넣고 측정한 값을 two sample t-test 방법으로 통계적 유의성을 검증하였다. 모든 통계 처리의 유의성 검증은 α= 0.05로 정하였다.The results were expressed as mean ㅁ standard deviation. The degree of increase in glucose uptake in 3T3-L1 adipocytes compared with the control group of the extract fraction was determined by adding only 1 ng / ml of insulin, 1 ng / ml of insulin, And the values were measured by two-sample t-test. The significance test of all statistical procedures was set to α = 0.05.
3T3-L1 지방세포에 인슐린 농도에 따른 포도당 흡수 정도를 측정한 결과, 3T3-L1 지방세포에 인슐린 1ng/㎖와 본 발명의 추출 분획 0.3㎍/㎖를 함께 처리하였을때, 인슐린의 농도가 25ng/㎖까지는 인슐린 농도가 증가함에 따라 포도당 흡수가 증가하였으나, 25ng/㎖보다 높은 인슐린 농도에서는 세포내로의 포도당 흡수가 인슐린 농도에 따른 차이가 없었다. 또한 0.3㎍/㎖ 추출 분획을 1ng/㎖의 인슐린과 함께 처리하였을 경우, 60% 메탄올 분획(Fr.4) 및 80% 메탄올 분획(Fr.5)은 포도당 흡수를 증가시켰다. 특히 80% 메탄올 분획(Fr.5)의 경우 인슐린을 50ng/㎖으로 처리하였을 때보다 포도당 흡수가 더 많이 증가하였다.When 3T3-L1 adipocytes were treated with 3 ng / ml of insulin and 0.3 μg / ml of the extract fraction of the present invention, the concentration of insulin in the 3T3-L1 adipocytes was 25 ng / ㎖, glucose uptake was increased with increasing insulin concentration. However, glucose uptake into the cell was not different according to insulin concentration at higher insulin concentration than 25ng / ㎖. In addition, 60% methanol fraction (Fr.4) and 80% methanol fraction (Fr.5) increased glucose uptake when 0.3 μg / ml extract fraction was treated with 1 ng / ml insulin. Especially, 80% methanol fraction (Fr.5) showed more increase of glucose uptake than that of 50ng / ㎖ of insulin.
추출 분획의 양을 3㎍/㎖로 증가시켜 1ng/㎖의 인슐린과 함께 처리하였을 경우, 20% 탄올 분획(Fr.2), 60% 메탄올 분획 (Fr.4), 80% 메탄올 분획(Fr.5) 및 100% 메탄올 분획(Fr.6)에서 포도당 흡수를 증가시켰다. When the amount of the extracted fraction was increased to 3 μg / ml and treated with 1 ng / ml of insulin, 20% ethanol fraction (Fr.2), 60% methanol fraction (Fr.4), 80% methanol fraction (Fr. 5) and 100% methanol fraction (Fr.6).
특히 60% 메탄올 분획(Fr.4), 80% 메탄올 분획(Fr.5)은 인슐린을 50ng/㎖으로 처리하였을 때보다 포도당 흡수가 더 많이 증가하였다. 따라서, 오미자의 60% 메탄올 분획(Fr.4), 80% 메탄올 분획(Fr.5)에서 인슐린 작용이 매우 향상된 것을 알 수 있다.Especially, 60% methanol fraction (Fr.4) and 80% methanol fraction (Fr.5) showed more glucose uptake than insulin treated 50ng / ㎖. Therefore, it can be seen that insulin action is greatly improved in the 60% methanol fraction (Fr.4) and the 80% methanol fraction (Fr.5) of Omija.
이때 추출 분획만 넣은 상태에서의 포도당 흡수값은 기저값과 유사하거나 오히려 낮아 분획물이 용제로 작용하여 비특이적으로 포도당의 흡수를 증가시키는 것은 아니라는 것을 알 수 있다.
At this time, it can be seen that the glucose uptake value in the presence of only the extracted fraction is similar to the base value, or rather low, so that the fraction acts as a solvent and does not nonspecifically increase the glucose uptake.
4. 세포막에 존재하는 GLUT 4 양의 변화4. Changes in the amount of
10㎠ 플레이트에 3T3-L1 지방세포를 옮긴 다음 날 3T3-L1 지방세포는 혈장 대신 3% 소혈청알부민을 첨가한 고농도 포도당 DMEM에서 12시간동안 배양한 후에 3 ㎍/㎖의 오미자 추출 분획을 첨가하고 5시간동안 배양한 후 0, 1 또는 50ng/㎖의 인슐린을 5분동안 처리하였다. 지방세포는 차가운 PBS로 반응을 중단시키고 바로 2 mM EDTA, 137 mM NaCl, 1% NP40, 10% 글리세롤 및 12 mM 알파-글리세롤 포스페이트와 프로테아제 저해제를 포함하는 20 mM 트리스(pH 7.4)로 구성된 용해완충액 (lysis buffer)으로 세포를 용출시켰다. After 3T3-L1 adipocytes were transferred to 10 cm 2 plates, 3T3-L1 adipocytes were cultured for 12 hours in high glucose DMEM supplemented with 3% bovine serum albumin instead of plasma, followed by addition of 3 μg / ml of Omija extract After incubation for 5 h, 0, 1 or 50 ng / ml of insulin was treated for 5 min. Adipocytes were terminated with cold PBS and immediately resuspended in lysis buffer consisting of 20 mM Tris (pH 7.4) containing 2 mM EDTA, 137 mM NaCl, 1% NP40, 10% glycerol and 12 mM alpha-glycerol phosphate and protease inhibitor and the cells were eluted with lysis buffer.
이 세포 용출액은 30분동안 얼음 속에 방치시킨 후 Kotani 등의 방법으로 세포막을 분리하였다. 분리한 세포막의 단백질 함량을 Lowry 방법으로 측정한 후 동량의 세포막 단백질에 유된 글루코스 트랜스포터 4(glucose transporter 4; GLUT 4) 함량을 안티-GLUT 4 항체(Chemicon, Temecula, CA)를 사용하여 immunoblotting 방법으로 측정하였다. The cell lysate was left in ice for 30 minutes and then the cell membrane was separated by Kotani et al. The protein content of the separated cell membranes was measured by the Lowry method and the content of glucose transporter 4 (GLUT 4) in the same amount of cell membrane protein was measured by immunoblotting method using an anti-GLUT 4 antibody (Chemicon, Temecula, CA) .
결과는 3 ㎍/㎖의 오미자의 60% 메탄올 분획(Fr.4) 및 80% 메탄올 분획(Fr.5)을 1 ng/㎖의 인슐린과 함께 처리하였을때, 세포막에 존재하는 GLUT 4의 양이 가장 높게 나타났으며, 인슐린 50 ng/㎖를 처리한 정도까지 증가하였다. 이는 추출액의 60% 메탄올 분획(Fr.4), 80% 메탄올 분획(Fr.5)이 인슐린 신호 전달 체계를 향상시켜 인슐린 작용을 증진하여 세포막에 GLUT 4의 양이 증가한 것이다.The results showed that the amount of
따라서, 세포막의 GLUT 4의 증가는 포도당 흡수를 증가시키는 것과 밀접한 관련이 있음 알 수 있다.
Therefore, the increase of GLUT4 in the cell membrane is closely related to the increase of glucose uptake.
(실험예 2 : 랫트에 대한 경구투여 급성 독성실험)(Experimental Example 2: Acute toxicity test for oral administration to rats)
본 발명의 조성물의 급성 독성을 알아보기 위하여, 하기와 같은 방법으로 급성독성실험을 하였다.In order to examine the acute toxicity of the composition of the present invention, an acute toxicity test was conducted as follows.
실험동물로 6주령의 특정병원체부재(specific pathogen-free, SPF) SD계 랫트를 사용하여 급성독성실험을 실시하였다. 군당 2 마리씩의 동물에 본 발명의 조성물을 각각 0.5% 메틸셀룰로즈 용액에 현탁하여 1g/㎏/㎖의 용량으로 1회 단회 구투여 하였다. 시험물질 투여 후 동물의 폐사여부, 임상증상, 체중변화를 관찰하고 혈액학적 검사와 혈액생화학적검사를 실시하였으며, 부검하여 육안으로 복강장기와 흉강장기의 이상여부를 관찰하였다.Acute toxicity tests were performed on 6-week-old specific pathogen-free (SPF) SD rats as experimental animals. The compositions of the present invention were each suspended in 0.5% methylcellulose solution and administered once at a dose of 1 g / kg / ml to animals of two mice per group. After the administration of the test substance, the mortality, clinical symptoms, and weight changes of the animals were observed, and hematological tests and blood biochemical tests were carried out, and autopsy was performed to observe the abnormalities of the abdominal organs and thoracic organs.
그 결과, 시험물질을 투여한 모든 동물에서 특기할 만한 임상증상이나 폐사된 동물은 없었으며, 체중변화, 혈액검사, 혈액생화학 검사, 부검소견 등에서도 독성변화는 관찰되지 않았다.As a result, there were no clinically symptomatic or dead animals in all the animals to which the test substance was administered, and no toxic change was observed in weight change, blood test, blood biochemical test, and autopsy findings.
따라서, 본 발명의 조성물은 모두 랫트에서 1g/㎏까지도 독성변화를 나타내지 않으며, 경구 투여 최소치사량(LD50)은 적어도 1g/kg 이상인 안전한 물질로 판단되었다. 하기에 본 발명의 조성물을 위한 제제예를 예시한다.
Therefore, the composition of the present invention did not exhibit any toxicity change even at 1 g / kg in rats, and it was judged that the oral LD50 was at least 1 g / kg or more. Examples of formulations for the composition of the present invention are illustrated below.
(제제예 1 : 약학적 제제의 제조)(Formulation Example 1: preparation of pharmaceutical preparation)
1. 산제의 제조1. Manufacturing of powder
추출물 2g, 유당 1g2g of extract, 1g of lactose
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above components were mixed and packed in airtight bags to prepare powders.
2. 정제의 제조 2. Preparation of tablets
추출물 100㎎, 옥수수전분 100㎎, 유당 100㎎, 스테아린산 마그네슘 2㎎100 mg of extract, 100 mg of corn starch, 100 mg of lactose, 2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
3. 캡슐제의 제조 3. Preparation of capsules
추출물 100㎎, 옥수수전분 100㎎, 유당 100㎎, 스테아린산 마그네슘 2㎎100 mg of extract, 100 mg of corn starch, 100 mg of lactose, 2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
(제제예 2 : 식품의 제조)(Formulation Example 2: Preparation of food)
본 발명의 추출물를 포함하는 식품들을 다음과 같이 제조하였다.Foods containing the extract of the present invention were prepared as follows.
1. 조리용 양념의 제조1. Preparation of cooking seasoning
본 발명의 추출물 20~95 중량%로 건강 증진용 조리용 양념을 제조하였다.Healthy cooking sauce was prepared from 20 to 95% by weight of the extract of the present invention.
2. 토마토 케찹 및 소스의 제조2. Manufacture of tomato ketchup and sauce
본 발명의 추출물 0.2~1.0 중량%를 토마토 케찹 또는 소스에 첨가하여 건강 증진용 토마토 케찹 또는 소스를 제조하였다.0.2 ~ 1.0 wt% of the extract of the present invention was added to tomato ketchup or sauce to prepare health-promoting tomato ketchup or sauce.
3. 밀가루 식품의 제조3. Manufacture of flour food
본 발명의 추출물 0.5~5.0 중량%를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.5 to 5.0% by weight of the extract of the present invention was added to wheat flour, and a bread, a cake, a cookie, a cracker and a noodle were prepared by using this mixture to prepare a food for health promotion.
4. 스프 및 육즙(gravies)의 제조4. Manufacture of soups and gravies
본 발명의 추출물 0.1~5.0 중량%를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1 to 5.0% by weight of the extract of the present invention was added to soups and gravies to prepare meat products for health promotion, soup of noodles and juices.
5. 그라운드 비프(ground beef)의 제조5. Manufacture of ground beef
본 발명의 추출물 10 중량%를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.10% by weight of the extract of the present invention was added to ground beef to prepare ground beef for health promotion.
6. 유제품(dairy products)의 제조6. Manufacture of dairy products
본 발명의 추출물 5~10 중량%를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.5 to 10% by weight of the extract of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
7. 선식의 제조7. Manufacturing of wires
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60메쉬의 분말로 제조하였다. 검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a known method, and then they were prepared into powders having a particle size of 60 mesh by a grinder.
본 발명의 추출물을 진공 농축기에서 감압ㅇ농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60메쉬로 분쇄하여 건조분말을 얻었다.The extract of the present invention was concentrated under reduced pressure in a vacuum concentrator, dried by spraying and dried in a hot air drier, and pulverized to a size of 60 mesh with a pulverizer to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 오미자 추출물의 건조분말을 다음의 비율로 배합하여 제조하였다. 곡물류(현미 30중량%, 율무 15중량%, 보리 20중량%), 종실류(들깨 7중량%, 검정콩 8중량%, 검정깨 7중량%), 오미자 추출물의 건조분말(3 중량%), 영지(0.5중량%), 지황(0.5중량%)
The above-prepared cereal grains, seeds and dried powder of the extract of Omiza were blended in the following proportions. (30% by weight of brown rice, 15% by weight of barley, 20% by weight of barley), seeds (7% by weight of perilla seeds, 8% by weight of black beans, 7% by weight of black sesame seeds) (0.5% by weight), sulfur (0.5% by weight)
(제제예 3 : 음료의 제조)(Formulation Example 3: Preparation of beverage)
1. 탄산음료의 제조1. Manufacture of carbonated beverages
한방차 추출물 50∼80중량%, 설탕 5~20중량%, 구연산 0.05~0.3중량%, 카라멜 0.005~0.02중량%, 비타민 C 0.1~1중량%의 첨가물을 혼합하고, 여기에 79~94중량%의 정제수를 혼합하여 된 탄산음료용 혼합물 20∼50중량%를 섞어서 시럽을 만든 다음, 상기 시럽을 85~98℃에서 20~180초간 살균하여 냉각수와 1:3.5∼4.5의 비율로 혼합한 다음 탄산가스를 0.5~0.82%를 주입하여 본 발명의 추출물을 함유하는 탄산음료를 제조하였다. 이때 설탕 5~10중량%로 혼합하고, 시럽과 냉각수는 1:4의 비율로 혼합하는 것이 바람직하다.A mixture of 50-80% by weight of herbal tea extract, 5-20% by weight of sugar, 0.05-0.3% by weight of citric acid, 0.005-0.02% by weight of caramel and 0.1-1% by weight of vitamin C, Purified water is mixed with 20 to 50% by weight of a mixture of carbonated beverages to make a syrup. The syrup is sterilized at 85 to 98 ° C for 20 to 180 seconds, mixed with cooling water at a ratio of 1: 3.5 to 4.5, 0.5 to 0.82% of gas was injected to prepare a carbonated drink containing the extract of the present invention. At this time, it is preferable to mix 5 to 10% by weight of sugar, and mix syrup and cooling water at a ratio of 1: 4.
2. 건강음료의 제조
한방차 추출물 50∼80중량%, 액상과당 0.3∼6.5중량%, 올리고당 1∼10중량%, 설탕 1∼10중량%, 식염 0.3∼6.5중량%, 물 68∼87중량%를 혼합하여 된 건강음료용 혼합물 20∼50중량%를 균질하게 배합하고 순간살균하여 제조된다.
일실시예로서, 액상과당(0.5중량%), 올리고당(2중량%), 설탕(2중량%), 식염(0.5중량%), 물(75중량%)과 같은 부재료 20∼50중량%와 한방차 추출물 50∼80중량%를 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.2. Manufacture of health drinks
A health drink containing 50 to 80% by weight of a herbal tea extract, 0.3 to 6.5% by weight of liquid fructose, 1 to 10% by weight of oligosaccharide, 1 to 10% by weight of sugar, 0.3 to 6.5% by weight of salt, and 68 to 87% 20 to 50% by weight of the mixture is uniformly blended and sterilized at a moment.
In one embodiment, 20 to 50% by weight of a supplementary material such as liquid fructose (0.5% by weight), oligosaccharide (2% by weight), sugar (2% by weight), salt (0.5% 50 to 80% by weight of tea extracts were uniformly blended and instant sterilized, and then packaged in small containers such as glass bottles and plastic bottles to produce health drinks.
삭제delete
3. 야채쥬스의 제조3. Manufacture of vegetable juice
본 발의 추출물 5g을 토마토 또는 당근 쥬스 1,000㎖에 가하여 건강 증진용 야채쥬스를 제조하였다.5 g of the extract of the present invention was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice for health promotion.
4. 과일쥬스의 제조4. Manufacture of fruit juice
본 발명의 추출물 1g을 사과 또는 포도 쥬스 1,000㎖에 가하여 건강 증진용 과일쥬스를 제조하였다.Health enhancing fruit juice was prepared by adding 1 g of the extract of the present invention to 1,000 ml of apple or grape juice.
12 : 냉각기 14 : 열교환기
16 : 펌프 17 : 용기12: cooler 14: heat exchanger
16: pump 17: container
Claims (5)
상기 분쇄된 한방생약재를 CO₂또는 N₂캐리어 기체를 이용한 초임계 추출농축기에 장입하고 밀폐된 상태에서 56~60℃ 온도, 기체부피가 8~19㎥/h인 조건에서 캐리어 기체가 폐쇄 회로공간에서 순환하면서, 열교환기(14) 내에 위치되는 농축물의 증기압이 낮아지고, 용매를 포함하는 담체는 냉각기(12)로 이동하여 용매가 응축되며 용기(17)에 모아진 후, 건조된 상기 캐리어 기체는 펌프(16)를 통하여 재순환되는 과정을 통해 한방생약재가 추출 및 농축이 되는 단계;
상기 농축 추출물은 병 또는 팩에 장입한 후 40~90℃에서 살균 포장하는 단계;를 포함하는 것을 특징으로 하는 초임계 추출법에 의한 한방차 추출조성물 제조방법10 to 20 wt% of silkworm, 5 to 10 wt% of Puerariae radix, 5 to 10 wt% of raw persimmon, 5 to 10 wt% of Omija, 5 to 10 wt% of licorice, 20 to 50 wt% Drying the herbal medicine at 40 to 60 DEG C and cutting the dried herbal medicine to 0.1 to 0.2 cm;
The pulverized herbal medicines are charged into a supercritical extraction concentrator using a CO 2 or N 2 carrier gas, and the carrier gas circulates in a closed circuit space at a temperature of 56 to 60 ° C. and a gas volume of 8 to 19 m 3 / h. The vapor pressure of the concentrate located in the heat exchanger 14 is lowered and the carrier containing the solvent is transferred to the cooler 12 and the solvent is condensed and collected in the vessel 17, 16) to extract and concentrate the oriental medicinal herb;
Wherein the concentrated extract is charged into a bottle or a pack and then sterilized and packaged at 40 to 90 ° C to prepare a herbal tea extract composition
상기 추출 및 농축이 되는 단계에서 고농도의 시럽이나 젤리 형태로 농축되어짐을 특징으로 하는 초임계 추출법에 의한 한방차 추출조성물 제조방법3. The method of claim 2,
Wherein the extract is concentrated in a high concentration of syrup or jelly in the step of extracting and concentrating the supernatant,
설탕 5∼20중량%, 구연산 0.05∼0.3중량%, 카라멜 0.005∼0.02중량%, 비타민C 0.1∼1중량%, 정제수 79∼94중량%를 혼합하여 된 탄산음료용 혼합물 20∼50중량%를 섞어서 시럽을 만든 다음,
상기 시럽을 85∼98℃에서 20∼80초간 살균하여 냉각수와 1:3.5∼4.5의 중량비로 혼합한 다음 탄산가스를 주입하여 제조됨을 특징으로 하는 탄산음료 제조방법.50 to 80% by weight of a herbal tea extract composition prepared by the method of claim 2 or 3,
And 20 to 50% by weight of a mixture for carbonated drinks obtained by mixing 5 to 20 wt% of sugar, 0.05 to 0.3 wt% of citric acid, 0.005 to 0.02 wt% of caramel, 0.1 to 1 wt% of vitamin C and 79 to 94 wt% of purified water After making the syrup,
Sterilizing the syrup at 85 to 98 캜 for 20 to 80 seconds, mixing the mixture with cooling water at a weight ratio of 1: 3.5 to 4.5, and then injecting carbonic acid gas.
액상과당 0.3∼6.5중량%, 올리고당 1∼10중량%, 설탕 1∼10중량%, 식염 0.3∼6.5중량%, 물 68∼87중량%를 혼합하여 된 건강음료용 혼합물 20∼50중량%를 균질하게 배합하고 순간살균하여 제조됨을 특징으로 하는 건강음료 제조방법.50 to 80% by weight of a herbal tea extract composition prepared by the method of claim 2 or 3,
20 to 50% by weight of a mixture for health drinks mixed with 0.3 to 6.5% by weight of liquid fructose, 1 to 10% by weight of oligosaccharide, 1 to 10% by weight of sugar, 0.3 to 6.5% by weight of salt, and 68 to 87% ≪ / RTI > and then sterilized in an instant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140178078A KR101774769B1 (en) | 2014-12-11 | 2014-12-11 | Composition for medicinal herbal tea and manufacturing method of composition for medicinal herbal by supercritical fluid extraction and manufacturing method of carbonated beverage and health beverage thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140178078A KR101774769B1 (en) | 2014-12-11 | 2014-12-11 | Composition for medicinal herbal tea and manufacturing method of composition for medicinal herbal by supercritical fluid extraction and manufacturing method of carbonated beverage and health beverage thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160071489A KR20160071489A (en) | 2016-06-22 |
KR101774769B1 true KR101774769B1 (en) | 2017-09-06 |
Family
ID=56364767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140178078A KR101774769B1 (en) | 2014-12-11 | 2014-12-11 | Composition for medicinal herbal tea and manufacturing method of composition for medicinal herbal by supercritical fluid extraction and manufacturing method of carbonated beverage and health beverage thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101774769B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230103222A (en) | 2021-12-31 | 2023-07-07 | 박진섭 | Low calorie soft Sujeonggwa drink and Process for Preparation thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107950712A (en) * | 2017-12-05 | 2018-04-24 | 河北林益堂药业有限公司 | A kind of chrysanthemum Ge Yu essence tea |
KR102261238B1 (en) * | 2020-10-29 | 2021-06-07 | 하태걸 | Functional tea drink having snail mucus and medical herb and manufacturing method thereof |
CN114145401A (en) * | 2021-11-03 | 2022-03-08 | 瑞腾丰科技发展(北京)有限公司 | Soda water containing food and medicine homologous herbal plant extract and preparation method thereof |
-
2014
- 2014-12-11 KR KR1020140178078A patent/KR101774769B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230103222A (en) | 2021-12-31 | 2023-07-07 | 박진섭 | Low calorie soft Sujeonggwa drink and Process for Preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20160071489A (en) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20070111623A (en) | Pharmaceutical composition for treating or preventing diabetic complication containing an extract of chinese herb as an effective ingredient | |
KR101346244B1 (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
CN104982599A (en) | Botanic herbal tea concentrate and low-sugar botanic herbal tea beverage | |
KR20200004942A (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
KR101774769B1 (en) | Composition for medicinal herbal tea and manufacturing method of composition for medicinal herbal by supercritical fluid extraction and manufacturing method of carbonated beverage and health beverage thereof | |
KR101756804B1 (en) | Functional composition for anti-inflammation and anti-diabetic comprising the extract from a leaf of Angelica gigas Nakai and manufacturing method for functional sauce using the same | |
KR100771524B1 (en) | Composition for improving liver function comprising herbal mixture extract | |
KR100771525B1 (en) | Composition for removing hangover comprising herbal mixture extract | |
KR20040073651A (en) | Preparation method of functional drink and tea containing Curcuma longa L. | |
KR102149254B1 (en) | Pharnaceutical composition for prevention or treatment of diabetes comprising the mixed extract of vegetable natural products having the effect on removal of swelling and health functional food for prevention or improvement of diabetes comprising the same | |
EP1968401B1 (en) | Functional food composition for treating allergy, natural tea using the same and the manufacturing method thereof | |
CN106306206A (en) | Method for producing instant tea with green tea and effects of reducing blood glucose and blood lipid | |
KR20190053108A (en) | A composition comprising the complex extract for antiobesity of men | |
CN108925807A (en) | A kind of solid beverage and preparation method thereof of hypoglycemic decompression | |
KR20010039199A (en) | A health drink and its manufacturing process | |
KR20140146378A (en) | A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds | |
KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
KR101971986B1 (en) | Composition comprising Silverberry like taxillus extract for preventing or treating cancer | |
KR101181347B1 (en) | Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extracts of Dictamnus dasycarpus as active ingredient | |
KR101811227B1 (en) | Composition for Immune Enhancement, Fatigue Recovery, Physiologically Active, Detoxification Comprising Extracts of Lycium chinence miller, Rubus coreanus Miq. & Schisandra chinensis | |
KR101154031B1 (en) | Composition for Antifati gue containin g herbal mixture extract as in gredient compounds | |
KR102651713B1 (en) | Chocolate composition for relieving hangovers comprising Hovenia Dulcis fruit and Velvet Antlers, and the manufacturing method of chocolate for relieving hangovers using the same | |
KR102494072B1 (en) | Composition for improving or preventing depression comprising herbal extracts and method for preparing thereof | |
KR102173223B1 (en) | Food composition containing extract of roasted codonopsis lanceolata or roasted platycodon grandiflorum | |
KR20240080746A (en) | Preparation method of granule for capsule herb tea having gastrointestinal protective effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) |